

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2009213738 B2**

(54) Title  
**Monoclonal antibodies for tumor treatment**

(51) International Patent Classification(s)  
**C07K 16/30** (2006.01)      **A61K 39/395** (2006.01)

(21) Application No: **2009213738**      (22) Date of Filing: **2009.02.11**

(87) WIPO No: **WO09/101611**

(30) Priority Data

(31) Number <b>61/116,319</b>	(32) Date <b>2008.11.20</b>	(33) Country <b>US</b>
<b>61/027,501</b>	<b>2008.02.11</b>	<b>US</b>
<b>61/037,340</b>	<b>2008.03.18</b>	<b>US</b>

(43) Publication Date: **2009.08.20**  
(44) Accepted Journal Date: **2015.01.22**

(71) Applicant(s)  
**CURETECH LTD.**

(72) Inventor(s)  
**Rotem-Yehudar, Rinat;Rodionov, Galina**

(74) Agent / Attorney  
**PIPERS, Pipers Melbourne U 9B 9 Beach ST, Melbourne, VIC, 3207**

(56) Related Art  
**WO 2003/099196 A2**  
**WO 2006/021955 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 August 2009 (20.08.2009)

(10) International Publication Number  
WO 2009/101611 A1

(51) International Patent Classification:  
*C07K 16/30* (2006.01)   *A61K 39/395* (2006.01)

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:  
PCT/IL2009/000153

(22) International Filing Date:  
11 February 2009 (11.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/027,501   11 February 2008 (11.02.2008)   US  
61/037,340   18 March 2008 (18.03.2008)   US  
61/116,319   20 November 2008 (20.11.2008)   US

(71) Applicant (for all designated States except US):  
**CURETECH LTD.** [IL/IL]; 42 Hayarkon Street, 81227 Yavne (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROTEM-YEHUDAR, Rinat** [IL/IL]; 1 Yaakov Meridor Street, 69411 Tel Aviv (IL). **RODIONOV, Galina** [IL/IL]; 16 Ha'amoraim Street, 81208 Yavne (IL).

(74) Agents: **WEBB & ASSOCIATES** et al.; P.O. Box 2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2009/101611 A1

(54) Title: MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT

(57) Abstract: The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent.

**MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT****FIELD OF THE INVENTION**

The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent.

**5 BACKGROUND OF THE INVENTION**

The rapid increase of knowledge in recent years about the molecular and cellular bases of immune regulation, particularly at the level of T cell responses, provides a new arsenal of immunotherapeutic approaches including the development of tumor vaccines. Certain monoclonal antibodies were shown to have immunomodulatory activity including the ability to bind determinants on the surface of T cells and to induce proliferation, activation, maturation or differentiation of these cells.

10 BAT (also referred to as mBAT-1 or BAT-1) is a murine monoclonal antibody generated against a membrane preparation of a Burkitt lymphoma cell line (Daudi) that was shown to exhibit antitumor and immunostimulatory effects towards various types of tumors (Hardy et al., 2001, Int. J. Oncol. 19:897). This monoclonal antibody was initially disclosed in U.S. Patent No. 5,897,862 to Hardy et al. BAT-1 is secreted by the hybridoma cell line having CNCM Accession No. I-1397.

15 The polynucleotide and amino-acid sequences of murine BAT are disclosed in WO 00/58363, to Hardy et al., and U.S. Patent Publication No. 2003/0026800. A number of humanized monoclonal antibodies based on murine BAT are disclosed in U.S. Patent Application Publication No. 2008/0025980. According to the disclosure, the humanized monoclonal BAT antibody appears to induce a greater antitumor effect than those induced by the parent murine BAT antibody. Among various model systems tested, the BAT antitumor activity was studied in SCID (severe combined immunodeficiency disease) mice, beige mice that are deficient in NK cells and nude mice that are deficient in T cells (Hardy, B., 1997, Proc. Natl. Acad. Sci. USA

94:5756). All mice were injected intravenously with murine B16 melanoma that subsequently develops tumors in the lungs. BAT exerted an antitumor effect only in SCID mice that were engrafted with either murine or human lymphocytes. In the athymic nude mice and the beige mice BAT exerted an antitumor activity, though this 5 activity was less effective as compared to the antitumor activity of BAT in the wild-type mice.

The immunomodulatory effect of murine BAT was studied also *in vitro*. Murine BAT activates CD4+ T cells and induces the secretion of IFN- $\gamma$  from these cells (Hardy et al., 2000, *Int. Immunol.* 12:1623 and Quaglino E. et al., 2005, *Vaccine* 10 9:23(25):3280-7, respectively). In addition, it was found that BAT triggers the proliferation of T cells and increases their cytolytic activity (Hardy, B. et al., 1997, *Hum. Antibodies*, 8:95).

Berger et al. (2008) discloses administration of the humanized monoclonal antibody CT-011, which is based on mBAT-1, to patients with advanced hematologic 15 malignancies, and associated pharmacokinetics (Berger et al. *Clin. Cancer Res.* 2008;14(10) May 15, 2008).

It should be borne in mind that BAT antibodies are not expected to target the tumor cells themselves but rather the immune-functioning cells of the subject or patient, in order to modulate the immune response in a beneficial way.

20 One of the most widely used therapeutic treatments of cancer is chemotherapy. Chemotherapy drugs are divided into several groups based on their effect on specific chemical substances within cancer cells, the cellular activities or processes the drug interferes with, or the specific phases of the cell cycle the drug affects. Chemotherapy groups include: alkylating agents, nitrosoureas, antimetabolites, anthracyclines, 25 topoisomerase I and II inhibitors, mitotic inhibitors and steroid inhibitors.

A chemotherapeutic drug may be provided as a sole therapy but is often used in combination with one or more other active agents. In some instances, specific combinations have been adapted to provide significantly better clinical results. For example, the antimetabolite fluorouracil (5FU) and the alkylating agent oxaliplatin, are 30 used together in a combination regimen for the treatment of colorectal cancer. The combination therapy of fluorouracil, leucovorin (folinic acid) and oxaliplatin, also indicated for colorectal cancer, has been abbreviated as FOLFOX. The combination

therapy of cyclophosphamide, doxorubicin, vincristine and prednisone (abbreviated as CHOP) is used for the treatment of non-Hodgkin lymphoma, and the combination of CHOP and the chimeric monoclonal antibody rituximab (abbreviated as R-CHOP) is used for the treatment of diffuse large B cell lymphoma and other aggressive B-cell 5 non-Hodgkin lymphomas.

A combination therapy of uracil, 5FU or uracil mustard with radiation and with a monoclonal antibody, which specifically binds to an extracellular domain of a VEGF receptor, is disclosed in U.S. Patent No. 6,811,779. This combined therapy is directed to inhibit angiogenesis. U.S. Patent No. 6,217,866 discloses a method for inhibiting the 10 growth of human tumor cells that express human EGF receptors comprising administering an effective amount of an anti-neoplastic agent and an effective amount of a monoclonal antibody to a human cancer patient having said tumor cells; (i) wherein said antibody binds to the extra-cellular domain of the human EGF receptor of said tumor cell; (ii) wherein the antibody is not conjugated to the anti-neoplastic agent; and 15 (iii) wherein the antibody inhibits the binding of EGF to the EGF receptor.

Nowhere in the background art is it taught or suggested that use of a humanized mBAT-1 monoclonal antibody in combination with chemotherapy will be advantageous. In fact, since BAT and antibodies based thereon are known to have immunomostimulatory properties, it is highly surprising and unexpected that such 20 antibodies in combination with cytotoxic or other chemotherapeutic drugs that act by killing proliferating cell populations can be used to achieve greater clinical efficacy than each type of agent on its own.

## SUMMARY OF THE INVENTION

25 The present invention provides methods for inhibiting tumor growth, reducing tumor volume, increasing survival of a subject and inducing protection against tumor recurrence in subjects bearing solid and non-solid tumors. The methods comprise use of a humanized monoclonal antibody having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework 30 region (FR) derived from an acceptor human immunoglobulin. An example of such an antibody is hBAT-1 (also referred to herein as CT-011). Some of the methods disclosed herein preferably comprise use of the humanized monoclonal antibody in a combination

regimen with at least one chemotherapeutic agent, whereas other methods disclosed herein relate to use of the humanized monoclonal antibody on its own, but which can optionally be employed in combination with one or more chemotherapeutic agents.

The principles of the invention are demonstrated herein using both mBAT-1 and 5 CT-011 in lymphocyte cultures and in animal tumor models, and CT-011 in human patients having various types of hematologic tumors.

The invention is based, in part, on the unexpected discovery that the incorporation of CT-011 to a treatment regimen with various chemotherapeutic agents results in several beneficial antitumor and anticancer effects, including for example, reduction in 10 the rate of tumor growth, inhibition of tumor growth, and increased survival time, as compared to monotherapies with either of the treatments alone. It has also been found that incorporation of a humanized antibody such as CT-011 into a chemotherapy regimen can provide the additional benefit of increased tolerability to dose-limiting toxicity (DLT) levels of a chemotherapeutic agent.

15 The invention is also based, in part, on the observation that treatment of induced tumors in animal models with the subject antibodies, either alone or in combination with a chemotherapeutic agent, results in both a "cure", as well as a memory effect for long-term protection against tumor recurrence upon subsequent challenge with the same tumor cells. Animals cured by treatment with the humanized antibody CT-011 were 20 thus rendered resistant to recurrence or re-exposure to the tumor. Furthermore, it is now disclosed that in certain instances human subjects undergoing early stage clinical trials with CT-011 also demonstrate long-term tumor control and protection effects after the administration of a single dose of this antibody and its elimination from the blood.

Without wishing to be bound by any theory or mechanism of action, the activity of 25 humanized BAT monoclonal antibody in protecting against tumor recurrence or resurgence may be associated with the activity of such an antibody in protecting effector/memory T cells from apoptosis, as disclosed herein and exemplified with antibody CT-011.

Thus, in various aspects, the present invention provides combinations of antitumor 30 agents that are not hitherto known to exert a cumulative or even an additive effect. According to certain principles of the invention, the combinations comprise one treatment which is administration of at least one chemotherapeutic agent, and another

different treatment which is administration of an immunostimulatory humanized monoclonal antibody based on mBAT-1. Unexpectedly, the two treatments achieve a greater beneficial antitumor effect when used in combination, than when used separately or each on its own. Combination therapy as used herein and in the claims may refer to 5 any of a number of different combination treatments, including for example, substantially overlapping periods of administration of two or more treatments; simultaneous, sequential or successive administration of two or more treatments, or scheduled administration of two or more treatments during alternating time periods.

According to a first aspect, the present invention provides a method of treating a 10 tumor, the method comprising (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the 15 subject an effective amount of at least one chemotherapeutic agent; thereby treating the tumor.

According to another aspect, the invention further provides a method of improving 20 tolerability to at least one chemotherapeutic agent, the method comprising administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; wherein the subject is undergoing chemotherapy with at least one chemotherapeutic agent; thereby improving tolerability to said chemotherapeutic agent.

According to yet another aspect of the invention, there is provided a method of 25 enhancing survival or inhibiting disease progression in a subject having a tumor, wherein the subject is treated with at least one chemotherapeutic agent, the method comprising administering an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; thereby enhancing survival of the subject.

According to yet another aspect, the invention provides a method of reducing or preventing tumor recurrence, the method comprising administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; thereby reducing or preventing tumor recurrence.

According to one embodiment, the method of reducing or preventing tumor recurrence further comprises administering to the subject at least one chemotherapeutic agent.

According to particular embodiments, the subject is undergoing or has completed a course of chemotherapy with at least one chemotherapeutic agent.

According to various embodiments, the light chain variable region of the humanized monoclonal antibody is characterized by the formula:

15 FR<sub>L1</sub>-CDR<sub>L1</sub>-FR<sub>L2</sub>-CDR<sub>L2</sub>-FR<sub>L3</sub>-CDR<sub>L3</sub>-FR<sub>L4</sub>

wherein each FR is independently a framework region of a human antibody and each CDR is independently a complementarity determining region of the monoclonal mBAT-1 antibody.

According to various embodiments, the heavy chain variable region of the humanized monoclonal antibody is characterized by the formula:

FR<sub>H1</sub>-CDR<sub>H1</sub>-FR<sub>H2</sub>-CDR<sub>H2</sub>-FR<sub>H3</sub>-CDR<sub>H3</sub>-FR<sub>H4</sub>

wherein each FR is independently a framework region of a human antibody and each CDR is independently a complementarity determining region of the monoclonal mBAT-1 antibody.

25 According to various embodiments, the FRs are derived from the light chain variable region of the human TEL9 antibody (SEQ ID NO: 130), or modified therefrom.

According to various embodiments, the FR amino acid sequences derived or modified from the light chain variable region of the human TEL9 antibody are selected from the group consisting of: FR<sub>L1</sub>, [EIVLT QSPSS LSASV GDRVT ITC; SEQ ID NO: 1]; FR<sub>L2</sub>, [W (F or Y) QQKPG KAPKL (W or L) IY; SEQ ID NO: 2]; FR<sub>L3</sub>, [GVPSR FSGSG SGT (D or S) (Y or F) (C or T) LTINS LQPED FATYY C; SEQ ID

NO: 3]; and FR<sub>H4</sub>, [FGGGT KLEIK; SEQ ID NO: 4].

According to various embodiments, the FRs are derived from the heavy chain variable region of the human hsgiv1295 antibody (SEQ ID NO: 146), or modified therefrom.

According to various embodiments, the FR amino acid sequences derived or modified from the heavy chain variable region of the human hsgiv1295 antibody are selected from the group consisting of: FR<sub>H1</sub>, [Q (I or V) QLV QSGSE LKKPG ASVKI SCKAS GY (T or S) F (T or S); SEQ ID NO: 5]; FR<sub>H2</sub>, [WV (R OR K) QAPGQ GL (Q or K) WMG; SEQ ID NO: 6]; FR<sub>H3</sub>, [RF (V or A) FSLDT SV (N or S) TAYLQ ITSL (T or N) AEDTG MYFC (V or A) (R or K); SEQ ID NO: 7]; and FR<sub>H4</sub>, [WGQGT LVTVS S; SEQ ID NO: 8].

According to various embodiments, the light chain variable region comprises at least one amino acid sequence selected from the group consisting of: CDR<sub>L1</sub> [SARSS VSYMH; SEQ ID NO: 9]; CDR<sub>L2</sub> [RTSNL AS; SEQ ID NO: 10]; CDR<sub>L3</sub> [QQRSS FPLT; and SEQ ID NO: 11], wherein the CDRs are derived from the murine BAT-1 antibody and the subscripts "L" and "H" refer to light and heavy chain regions, respectively.

According to various embodiments, the heavy chain variable region comprises at least one amino acid sequence selected from the group consisting of: CDR<sub>H1</sub> [NYGMN; SEQ ID NO: 12]; CDR<sub>H2</sub> [WINTD SGEST YAEF KG; SEQ ID NO: 13]; and CDR<sub>H3</sub> [VGYDA LDY; SEQ ID NO: 14].

According to various embodiments, the humanized antibody comprises: a light chain variable region selected from the group consisting of: BATR<sub>κA</sub> (SEQ ID NO: 15), BATR<sub>κB</sub> (SEQ ID NO: 16), BATR<sub>κC</sub> (SEQ ID NO: 17), and BATR<sub>κD</sub> (SEQ ID NO: 18); and a heavy chain variable region selected from the group consisting of: A (SEQ ID NO: 20), BATR<sub>Hb</sub> (SEQ ID NO: 21), BATR<sub>Hc</sub> (SEQ ID NO: 22), BATR<sub>Hd</sub> (SEQ ID NO: 23) and BATR<sub>He</sub> (SEQ ID NO: 24).

According to yet other embodiments, the humanized antibody comprises variable regions selected from the group consisting of: BATR<sub>Hb</sub>/BATR<sub>κA</sub> (SEQ ID NO: 20/SEQ ID NO: 15), BATR<sub>Hb</sub>/BATR<sub>κA</sub> (SEQ ID NO: 21/SEQ ID NO: 15), BATR<sub>Hb</sub>/BATR<sub>κB</sub> (SEQ ID NO: 21/SEQ ID NO: 16), BATR<sub>Hc</sub>/BATR<sub>κB</sub> (SEQ ID NO: 22/SEQ ID NO: 16), BATR<sub>Hb</sub>/BATR<sub>κD</sub> (SEQ ID NO: 21/SEQ ID NO: 18), and

BATRH<sub>C</sub>/BATR<sub>KD</sub> (SEQ ID NO: 22/SEQ ID NO: 18).

According to various preferred embodiments, the humanized monoclonal antibody has variable regions corresponding to BATRH<sub>C</sub>/BATR<sub>KD</sub> (SEQ ID NO: 22/SEQ ID NO: 18).

5 According to various embodiments, the antitumor activity of the humanized antibody or a fragment thereof is similar or greater than mBAT-1.

According to various embodiments, the fragment of the humanized antibody is selected from the group consisting of: Fv, F (ab'), F (ab') 2, and a single chain antibody.

10 The humanized monoclonal antibody of the invention is preferably generated by recombinant DNA technology, utilizing CDR grafting. Accordingly, the humanized antibody is produced by expression of polynucleotides, wherein the polynucleotides may encode the whole humanized antibody or the light chain variable region or the heavy chain variable region or the variable region of both chains of the humanized antibody. Further, the humanized antibody may be expressed in a host cell following co-15 transfection of distinct vectors each comprising polynucleotides encoding the heavy or the light chain, or by transfection of a single vector comprising both light and heavy chain polynucleotide sequences.

According to various embodiments, the light chain of the humanized antibody is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID 20 NO: 87, SEQ ID NO: 88, and SEQ ID NO: 89.

According to various embodiments, the heavy chain of the humanized antibody is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO: 90, SEQ ID NO: 91, and SEQ ID NO: 92.

25 According to various embodiments, the at least one chemotherapeutic agent is selected from the group consisting of: antimetabolites, platinum-based drugs, mitotic inhibitors, anthracycline antibiotics, topoisomerase inhibitors, anti-angiogenic agents and combinations thereof.

According to a currently preferred embodiment, the at least one chemotherapeutic agent is selected so that hBAT-1 enhances survival of lymphocytes when used in 30 combination with the chemotherapeutic agent. Typically, the enhanced or increased survival may be conveniently assayed in vitro, as exemplified hereinbelow.

According to some embodiments, the at least one chemotherapeutic agent is an antimetabolite, including purine antagonists, pyrimidine antagonists and folate antagonists. According to some embodiments, the antimetabolite is a pyrimidine antagonist. According to some embodiments, the antimetabolite is selected from the 5 group consisting of: 5-fluorouracil, uracil mustard, uracil, capecitabine, 6-mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine, and pemetrexed.

According to some embodiments, the at least one chemotherapeutic agent is 5-fluorouracil.

According to some embodiments, the at least one chemotherapeutic agent is 10 cytarabine.

According to some embodiments, the at least one chemotherapeutic agent is a platinum-based drug selected from the group consisting of: cisplatin, carboplatin and oxaliplatin.

According to yet other embodiments, the at least one chemotherapeutic agent is a 15 mitotic inhibitor selected from the group consisting of: paclitaxel, docetaxel, etoposide, vinblastine, vincristine and vinorelbine.

According to yet other embodiments, the at least one chemotherapeutic agent is an anthracycline antibiotic selected from the group consisting of: daunorubicin, respinomycin D and idarubicin.

20 According to some embodiments, the at least one chemotherapeutic agent is an anti-angiogenic agent selected from the group consisting of: bevacizumab, dopamine, tetrathiomolybdate, and antiangiogenic variants of VEGF.

According to some embodiments, the at least one chemotherapeutic agent is other 25 than a topoisomerase I inhibitor. According to some embodiments, the at least one chemotherapeutic agent is other than an alkylating agent.

According to various embodiments, the administering of the humanized antibody and of the at least one chemotherapeutic agent is carried out substantially simultaneously, concurrently, alternately, sequentially or successively. In some embodiments, the humanized antibody and the at least one chemotherapeutic agent are 30 administered according to overlapping schedules.

According to particular embodiments, administering of the humanized antibody is

carried out prior to initial administration of the at least one chemotherapeutic agent.

According to other embodiments, administering of either or both of the humanized antibody and the at least one chemotherapeutic agent is carried out by a route selected from the group consisting of intravenous, oral, intraperitoneal, subcutaneous, isolated limb perfusion, infusion into an organ and combinations thereof.

According to various embodiments, the methods further comprise treating the subject with radiation. According to various embodiments, the methods comprise all of administering the humanized antibody, administering the at least one chemotherapeutic agent and treating the subject with radiation.

According to some embodiments, the humanized antibody, the at least one chemotherapeutic agent and radiation treatment are administered substantially simultaneously, concurrently, alternately, successively or according to overlapping schedules.

In particular embodiments, the methods of the invention further comprise assessing at least one parameter selected from the group consisting of: rate of tumor growth, tumor volume, number of metastases, tumor recurrence and combinations thereof.

In some embodiments, the tumor is a solid or a non-solid tumor. In some embodiments, the non-solid tumor is a hematologic malignancy. In particular embodiments, the tumor is selected from the group consisting of a colorectal carcinoma tumor; a non-small lung cancer (NSCLC) tumor; a small cell lung cancer (SCLC) tumor; a breast carcinoma tumor; a melanoma tumor; an ovarian carcinoma tumor; a cervical carcinoma tumor; a pancreatic cancer tumor; a head and neck carcinoma tumor; a gastrointestinal carcinoma tumor; an esophageal tumor; a hepatocellular carcinoma tumor; multiple myeloma; a renal cell carcinoma tumor; a prostate tumor; non-Hodgkin's lymphoma; Hodgkin's disease; mantle cell lymphoma; Kaposi's sarcoma; a squamous cell carcinoma tumor; a basal cell carcinoma tumor; acute myeloid leukemia (AML); chronic myelocytic leukemia (CML); acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).

According to various embodiments, the subject is a human or non-human mammal. According to various preferred embodiments, the subject is a human.

In an additional aspect, the invention provides use of (i) a humanized monoclonal

antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) at least one chemotherapeutic agent; for the preparation of a 5 medicament for treating a tumor.

In another aspect, the invention provides a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified 10 therefrom; for the treatment of a tumor in a subject undergoing chemotherapy with at least one chemotherapeutic agent.

In an additional aspect, the invention provides use of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified 15 therefrom, for the preparation of a medicament for improving tolerability to at least one chemotherapeutic agent in a subject undergoing chemotherapy with said at least one chemotherapeutic agent.

In an additional aspect, the invention provides a humanized monoclonal antibody 20 or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom, for improving tolerability to at least one chemotherapeutic agent in a subject undergoing chemotherapy with said at least one chemotherapeutic agent.

According to another aspect, the invention provides use of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified 25 therefrom; for the preparation of a medicament for enhancing survival or inhibiting disease progression in a subject having a tumor, wherein the subject is treated with at least one chemotherapeutic agent.

According to another aspect, the invention provides a humanized monoclonal

antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; for enhancing survival or inhibiting disease progression in a subject having a tumor, wherein the subject is treated with at least one chemotherapeutic agent.

According to yet another aspect, the invention provides use of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; for the preparation of a medicament of reducing or preventing recurrence of a tumor.

According to yet another aspect, the invention provides a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; for reducing or preventing recurrence of a tumor.

In particular embodiments, the subject has undergone, is undergoing, or is scheduled to undergo chemotherapy with at least one chemotherapeutic agent.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** shows the effect of hBAT-1 in an assay based on viability of lymphocytes, when added to cultures concomitantly with vehicle control (gray bars) or in combination with 5FU (0.5mg/ml, white bars) and incubated for 72 hours. **Fig. 1A.** hBAT-1 (0.5 or 0.75 ug/ml as indicated) activity in the absence and presence of 5FU, presented as % difference in cell survival. **Fig. 1B.** hBAT-1 (0.75ug/ml) activity in the absence and presence of 5FU, expressed by Area Under dose response Curve (AUC presented as % difference x ug/ml). The incubation time with hBAT-1 (72 hours) is indicated on the x-axis. **Fig. 1C.** The effect of 5FU or vehicle control in the functional assay presented as viable cells/ml. The incubation time with 5FU or vehicle control (72 hours) is indicated on the x-axis.

**Figure 2** shows the effect of hBAT-1 in an assay based on viability of lymphocytes when added to cultures 24 prior to addition of vehicle control (gray bars)

or 5FU (0.5mg/ml, white bars), followed by incubation for 72 hours. **Fig. 2A.** hBAT-1 (0.5 or 0.75 ug/ml as indicated) activity in the absence and presence of 5FU, presented as % difference in cell survival. **Fig. 2B.** hBAT-1 (0.75 ug/ml) activity in the absence and presence of 5FU, presented as Area Under a dose response Curve (AUC presented as % difference x ug/ml). The incubation time with hBAT-1 (72 hours) is indicated on the x-axis.

10 **Figure 3** shows the effect of hBAT-1 in an assay based on viability of lymphocytes when concomitantly added to cultures with vehicle control (gray bars) or in combination with SN-38 (active form of irinotecan at 0.1mg/ml, white bars) and incubated for 72 hours. **Fig. 3A.** hBAT-1 (0.5 or 0.75 ug/ml as indicated) activity in the absence and presence of SN-38, presented as % difference in cell survival. **Fig. 3B.** hBAT-1 (0.75 ug/ml) activity expressed by Area Under dose response Curve (AUC presented as % difference x ug/ml). The incubation time with hBAT-1 (72 hours) is indicated on the x-axis.

15 **Figure 4** shows the effect of hBAT-1 in an assay based on viability of lymphocytes when added to cultures 24 prior to addition of vehicle control (gray bars) or SN-38 (active form of irinotecan at 0.1ug/ml, white bars), followed by incubation for 72 hours. **Fig. 4A.** hBAT-1 (0.5 or 0.75ug/ml as indicated) activity in the absence and presence of SN-38, presented as % difference in cell survival. **Fig. 4B.** hBAT-1 (0.75 ug/ml) activity expressed as Area Under a dose response Curve (AUC presented as % difference x ug/ml). The incubation time with hBAT-1 (72 hours) is indicated on the x-axis.

20 **Figure 5** shows the effect of hBAT-1 in an assay based on viability of lymphocytes when added to cultures (at dose response concentrations of 0.25 to 1.25 ug/ml) concomitantly (**Fig. 5A**) or 24 prior to (**Fig. 5B**) addition of vehicle control (gray bars) or the indicated chemotherapeutic agent (white bars), followed by incubation for 72 hours. Cis, cisplatin (10ug/ml); Oxa, oxaliplatin (10ug/ml); Tax, paclitaxel (0.43ug/ml); Dac, dacarbazine (1ug/ml). hBAT-1 activity is presented as Area Under a dose response Curve (AUC presented as % difference x ug/ml). The incubation time with hBAT-1 (72 hours) is indicated on the x-axis.

25 **Figure 6** shows the effect of hBAT-1 (0.75 or 1 ug/ml, as indicated) in an assay based on viability of lymphocytes when added concomitantly to cultures with vehicle

control) (black bars) or in combination with a chemotherapeutic agent (white bars) followed by incubation for 72 hours. Chemotherapeutic agents used were: cytarabine at 2mg/ml (**Fig. 6A**), cyclophosphamide at 1mg/ml (**Fig. 6B**) and doxorubicin at 0.03mg/ml (**Fig. 6C**). hBAT-1 activity is presented as % difference in cell survival.

5 **Figure 7** shows the effect of hBAT-1 in an assay based on viability of isolated human CD4+ lymphocytes when added (at 0.75ug/ml) 24 prior to addition of vehicle control (black bars) or a chemotherapeutic agent (white bars), followed by incubation for 72 hours. Chemotherapeutic agents used were: 5FU at 1ug/ml (**Fig. 7A**) and cisplatin at 10ug/ml (**Fig. 7B**). hBAT-1 activity is presented as % difference in cell 10 survival.

15 **Figure 8** shows the antitumor effect in colorectal adenocarcinoma (CRC) bearing mice of vehicle (black circles); 5FU (20 mg/kg administered on days 6-9 and 15-16; white squares); hBAT-1 (10  $\mu$ g/mouse administered on day 10; black squares); and a combination regimen (white circles) of hBAT-1 (10  $\mu$ g/mouse administered on day 10) and 5FU (20 mg/kg administered on days 6-9 and 15-16).

**Figure 9** shows the antitumor effect in CRC bearing mice of 5FU (20 mg/kg administered on days 6-9, 15-17, 22-24 and 29-31; white squares) and a combination regimen (white triangles) of hBAT-1 (10  $\mu$ g/mouse administered on days 10, 18 and 25) and 5FU (20 mg/kg administered on days 6-9, 15-17, 22-24 and 29-31).

20 **Figure 10** shows percentage of survival of CRC bearing mice treated with vehicle (white circles); 5FU (20 mg/kg administered on days 6-9, 15-17, 22-24, 29-31, 36-38 and 43-45; black triangles); hBAT-1 (10  $\mu$ g/mouse administered on days 10, 18, 25, 32 and 39; black squares); and a combination regimen (black diamonds) of hBAT-1 (10  $\mu$ g/mouse administered on days 10, 18, 25, 32 and 39) and 5FU (20 mg/kg administered 25 on days 6-9, 15-17, 22-24, 29-31, 36-38 and 43-45).

**Figure 11** shows percentage of survival of mice injected with B16 melanoma cells and treated with 5FU (50 mg/kg administered on days 1-4 and 7-8; black diamonds) or a combination regimen (white squares) of hBAT-1 (10  $\mu$ g/mouse administered on day 10) and 5FU (50 mg/kg administered on days 1-4 and 7-8).

30 **Figure 12** shows the antitumor effect, as evaluated by median tumor volume, upon treatment with vehicle (black circles); irinotecan (100 mg/kg administered on days

7 and 15; black squares); hBAT-1 (10 µg/mouse administered on day 10; white circles); and a combination regimen (white triangles) of hBAT-1 (10 µg/mouse administered on day 10) and irinotecan (100 mg/kg administered on days 7 and 15) in CRC bearing mice.

5       **Figure 13** shows percentage of survival of CRC bearing mice treated with vehicle (black circles); irinotecan (100 mg/kg administered on days 7 and 15, 22 and 29; black triangles); hBAT-1 (10 µg/mouse administered on days 10, 18, 25 and 32; white squares); and a combination regimen (black diamonds) of hBAT-1 (10 µg/mouse administered on days 10, 18, 25 and 32) and irinotecan (100 mg/kg administered on 10 days 7 and 15, 22 and 29).

15       **Figure 14** shows the antitumor effect, as evaluated by the median tumor volume, upon treatment with vehicle (black circles); oxaliplatin (1mg/kg administered on days 4, 7-10, 14-17 and 22-23; white squares); and a combination regimen (black triangles) of hBAT-1 (10 µg/mouse administered on days 11 and 18) and oxaliplatin (1mg/kg administered on days 4, 7-10, 14-17 and 22-23) in CRC bearing mice.

20       **Figure 15** shows percentage of survival of CRC bearing mice treated with vehicle (black circles); oxaliplatin (1mg/kg administered on days 4, 7-10, 14-17, 22-24, 29-31; white squares); and a combination regimen (black triangles) of hBAT-1 (10 µg/mouse administered on days 11, 18, 25 and 32) and oxaliplatin (1 mg/kg administered on days 4, 7-10, 14-17, 22-24, 29-31).

25       **Figure 16** shows the effect of a combination of hBAT-1 and a chemotherapeutic agent in protecting against tumor recurrence, as evaluated by median tumor volume (**Fig. 16A**) and percentage of survival (**Fig. 16B**). Mice (n=3) that had been cured of CRC for 2 or 5 months by a combination regimen of hBAT-1 and oxaliplatin, were then re-challenged with the same CRC cell line (white squares). In addition, naïve mice (n=6) were newly introduced with CRC (black circles).

30       **Figure 17** shows the effect of a combination of hBAT-1 and a chemotherapeutic agent in protecting against tumor recurrence, as evaluated by median tumor volume (**Fig. 17A**) and percentage of survival (**Fig. 17B**). Mice (n=2) that had been previously cured of CRC by a combination regimen of hBAT-1 and oxaliplatin, as indicated by the lack of tumor recurrence upon challenge with the same CRC cell line, were then re-challenged with breast carcinoma (white squares). Challenge with breast carcinoma was

carried out 2 months after mice exhibited resistance against CRC tumor recurrence. In addition, naïve mice (n=6) were newly introduced with CRC (black circles).

**Figure 18** shows the effect of CT-11 in an cell viability assay, using human CD4+CD45RO+ effector/memory T cells (black bars) and naïve CD4+CD45RO- T cells (white bars) treated with hBAT (1ug/ml), followed by incubation for 72 and 96 hours. Results are expressed as % difference in cell survival.

**Figure 19** shows the amino acid sequences of various embodiments of the humanized BAT-1 VK region (SEQ ID NOS. 15-18). Where the BAT-1  $\text{V}_\kappa$  region residues and the human TEL9  $\text{V}_\kappa$  region (SEQ ID NO. 130) sequence match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. Where an amino acid in the TEL9 FRs is changed in the humanized BAT-1  $\text{V}_\kappa$  region, it is highlighted in bold. The CDRs are described by the use of the nomenclature [==L1==]. The numbering used is as according to Kabat (Kabat et al., Sequences of proteins of immunological interest, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office, 1991).

**Figure 20** presents the amino acid sequences of various embodiments of the humanized BAT-1 VH region (SEQ ID NOS. 20-24). Where the BAT-1 VH region residues and the human hsighv1295 VH region (SEQ ID NO. 146) sequence match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. Where an amino acid in the hsighv1295 FRs is changed in the humanized BAT-1 VH region, it is highlighted in bold. The CDRs are described by the use of the nomenclature [==H1==], while [-----] denotes part of the H1 structural loop. The numbering used is as according to Kabat (Kabat et al., *ibid*).

## 25 DETAILED DESCRIPTION OF THE INVENTION

### Definitions

The term "antibody" (also referred to as an "immunoglobulin") is used in the broadest sense and specifically encompasses monoclonal antibodies (including full length monoclonal antibodies) and antibody fragments so long as they exhibit the desired biological activity. "Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody

fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

The basic unit of the naturally occurring antibody structure is a heterotetrameric glycoprotein complex of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains, linked together by both noncovalent associations and by disulfide bonds. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Five human antibody classes (IgG, IgA, IgM, IgD and IgE) exist, and within these classes, various subclasses, are recognized on the basis of structural differences, such as the number of immunoglobulin units in a single antibody molecule, the disulfide bridge structure of the individual units, and differences in chain length and sequence. The class and subclass of an antibody is its isotype.

The amino terminal regions of the heavy and light chains are more diverse in sequence than the carboxy terminal regions, and hence are termed the variable domains. This part of the antibody structure confers the antigen-binding specificity of the antibody. A heavy variable (VH) domain and a light variable (VL) domain together form a single antigen-binding site, thus, the basic immunoglobulin unit has two antigen-binding sites. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains (Chothia et al., J. Mol. Biol. 186, 651-63 (1985); Novotny and Haber, (1985) Proc. Natl. Acad. Sci. USA 82 4592-4596).

The carboxy terminal portion of the heavy and light chains form the constant domains i.e. CH1, CH2, CH3, CL. While there is much less diversity in these domains, there are differences from one animal species to another, and further, within the same individual there are several different isotypes of antibody, each having a different function.

The term "framework region" or "FR" refers to the amino acid residues in the variable domain of an antibody which are other than the hypervariable region amino acid residues as herein defined. The term "hypervariable region" as used herein refers to the amino acid residues in the variable domain of an antibody which are responsible for antigen binding. The hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR". The CDRs are primarily responsible

for binding to an epitope of an antigen. The extent of FRs and CDRs has been precisely defined (see, Kabat et al., *ibid*).

The term "acceptor human immunoglobulin" refers to the human immunoglobulin providing the framework for a humanized antibody.

5 As used herein, the term "humanized antibody" refers to an antibody comprising a framework region from a human antibody and one or more CDRs from a non-human (usually a mouse or rat) immunoglobulin. Parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. In some cases however, specific amino acid residues, for  
10 example in the framework regions, may be modified, so as to optimize performance of the humanized antibody. Importantly, the humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDRs. For further details, see e.g. U.S. Pat. No. 5,225,539 assigned to Medical Research Council, UK.

15 The terms "a framework region from an acceptor human immunoglobulin" and "a framework region derived from an acceptor human immunoglobulin", and similar grammatical expressions are used interchangeably herein to refer to a framework region or portion thereof that has the same amino acid sequence of the acceptor human immunoglobulin.

20 The term "a framework region modified from an acceptor human immunoglobulin" and similar grammatical expressions refers to a framework region that is altered in its amino acid sequence, for example by substitution or deletion or chemical modification of one or more amino acid residues, as compared to the sequence of the original acceptor human immunoglobulin. Modification in the FR region may be carried out so as to optimize performance of the humanized antibody being constructed, for  
25 example to optimize antigen binding and avoid steric clashes. A detailed explanation of the basis and rationale for modifying specific residues in the FR regions of an acceptor immunoglobulin for construction of a humanized BAT antibody is provided in U.S. Patent Application Publication No. 2008/0025980.

30 Further, an FR may be chemically modified at one or more amino acid residues, either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques. Chemical modifications include, without limitation, acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI

anchor formation, covalent attachment of a liquid or lipid derivative, methylation, myristylation, pegylation, prenylation, phosphorylation, ubiquitination, or any similar process.

The term "human antibody" refers to an antibody encoded by a gene actually occurring in a human, or an allele, variant or mutant thereof.

The term "antitumor effect" as used herein, refers to a beneficial biological effect, which can be manifested by any one or more of: a decrease or stabilization of tumor volume, a decrease or stabilization of the number of tumor cells, a decrease or stabilization of the rate of tumor growth, a decrease or stabilization of the number of metastases, protection from tumor recurrence, an increase in life expectancy or survival of the subject with the tumor, an increase in life expectancy or survival without disease progression of the subject with the tumor or amelioration of various physiological symptoms associated with the cancerous condition. An "antitumor effect" can also be manifested by the ability of the combination of the invention to prevent the occurrence of tumor in the first place or the recurrence of the tumor. Given its properties, the methods of the invention can be used in the treatment of acute cancer, of dormant, controlled or stabilized cancer, as well as in cancer prophylaxis.

The term "mammal" means any mammal, including pet animals, such as dogs and cats; farm animals, such as pigs, cattle, sheep, and goats; laboratory animals, such as mice and rats; primates, such as monkeys, apes, and chimpanzees; and preferably, humans.

The term "effective amount" with respect to the humanized antibody and the chemotherapeutic agent(s) of the invention should be understood as meaning an amount of each of these active agents required to achieve a therapeutic effect, without causing excessive or uncontrollable adverse side effects. The effective amount required to achieve the therapeutic end result may depend on a number of factors including, for example, the specific type of the tumor and the severity of the patient's condition, and whether the combination is further co-administered with radiation. The effective amount (dose) of the active agents, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the subject over time, including inhibition of tumor growth, reduction in the rate of tumor growth, prevention of tumor and metastasis growth and enhanced survival.

The term "enhanced survival", as used herein, refers to a prolonged length of time during which the subject or patient is alive following treatment with a method of the invention. Enhanced survival denotes the increased probability of staying free of disease progression for an individual suffering from cancer after a particular treatment. It is also 5 used to describe the elevated percentage of individuals in a group whose disease is likely to remain stable (not showing signs of progression) after a specified duration of time, compared to a control group. It is also used to describe the elevated percentage of individuals in a group whose disease is likely to be cured (not showing signs of disease) after a specified duration of time, compared to a control group. This parameter may be 10 measured by any one of the customary clinical endpoints denoted as "progression-free survival", "overall survival" and "disease free survival" used as an indication of the efficacy of a particular treatment.

The term "tolerability to chemotherapeutic agents" refers to the physiological, physicochemical and immunological capacity of a subject to tolerate the adverse side 15 effects associated with treatment with one or more chemotherapeutic agents. Accordingly, the term "improving tolerability to chemotherapeutic agents" refers to increasing the physiological and physicochemical capacity to such adverse side effects, such that the severity of the adverse side effects is decreased and/or the number of side effects is decreased. Accordingly, "improving tolerability to chemotherapeutic agents" 20 may refer to improving the quality of life of cancer patients treated with chemotherapeutic agents.

The term "tumor recurrence" refers to the re-emergence, reappearance, re-growth or proliferation of a tumor of the same type in either the same location or a different location, following a period during which the growth of the original tumor has been 25 reversed, arrested or inhibited.

The term "enhances or increases lymphocyte survival" as used herein refers to the ability of a particular combination of treatments to prolong the viability of lymphocytes in vitro or in vivo, as compared to the viability of an identical cell population with only one of the treatments. For example, certain combinations of hBAT-1 and 30 chemotherapeutic agents enhance lymphocyte survival, as assessed in an in vitro assay, as exemplified in Example 1 herein.

Methods of the Invention

Cancer immunotherapeutics are aimed by and large at modulating the response of the immune system to induce or enhance killing of tumor cells and control tumor growth. This approach utilizes using various immunomodulators including monoclonal 5 antibodies that selectively bind to specific determinants on T cells thereby either initiating an activation pathway or inducing an inhibitory effect.

According to certain aspects of the present invention, administration of the immunostimulatory humanized antibody in conjunction with at least one antitumor 10 chemotherapeutic agent acts to enhance the antitumor effect of chemotherapeutic agents, and vice versa. In preferred embodiments, the combinations of the immunostimulatory antibody together with the at least one chemotherapeutic agent improve the clinical outcome in a significant manner versus each of the treatments 15 alone. In a preferred embodiment, there is synergy when tumors are treated with the humanized antibody of the invention in conjunction with at least one chemotherapeutic agent, and, optionally further in conjunction with radiation.

In other words, according to one aspect of the present invention the antitumor effect of the humanized antibody of the invention is augmented more than expected when combined with at least one chemotherapeutic agent. Synergy may be shown by greater antitumor effect with combined treatment than would be expected from the 20 additive effect of treatment with the humanized antibody and the chemotherapeutic agent(s), each on its own. For example, synergy is demonstrated in Examples 2, 3 and 6 herein, which disclose that combination therapy according to the invention exerts an increased antitumor effect, as measured by both tumor volume and survival of tumor bearing mice, as compared to the effect of either the antibody or chemotherapy alone. 25 More specifically, in assessing effect on tumor volume, Figure 8 shows that administration of the combination of hBAT-1 and 5FU is advantageous over each agent on its own, and Figure 9 shows that the combination of hBAT-1 and 5FU is synergistic over 5FU on its own. Similarly, in assessing effect on survival, it has been demonstrated that administration of the combination of hBAT-1 and 5FU is advantageous over each 30 agent on its own (Figure 10) or over 5FU on its own (Figure 11). A different combination, namely hBAT-1 and oxaliplatin, is not only advantageous over oxaliplatin in increasing survival, but also induces complete remission in some of the subjects (Figure 15). Synergy is also demonstrated by complete remission and generation of

tumor-specific memory protection in tumor bearing mice treated with the combination therapy of the invention as compared to the corresponding monotherapies (Figures 10, 15, 16, 17).

The in vivo effects exerted by the combinations of the invention are supported by in vitro functional assays of lymphocyte cell survival as disclosed in Example 1 herein. As exemplified, sequential treatment of murine lymphocytes with hBAT-1 followed by 5FU (administered after a period of 24 hours) unexpectedly enhanced lymphocyte survival by approximately 30% (Figure 2A). Concomitant treatment of lymphocytes with hBAT-1 and 5FU only slightly increased lymphocyte survival (Figure 1A) compared to treatment with hBAT-1 alone, and 5FU on its own did not enhance cell survival (Fig. 1C), indicating mechanistic synergy of the sequential scheduled treatment. Synergistic activity was also observed in in vitro assays with the combination of the chemotherapeutic agent cisplatin and the humanized antibody (Figure 7B). Thus, combining certain chemotherapeutic agents, with the humanized antibody of the invention results in synergistic effects *in vitro* and *in vivo*.

The synergistic effect disclosed and exemplified herein is utterly unexpected, given that BAT antibodies and chemotherapeutic agents are known to have completely different and even opposing mechanisms of action and types of targets. That is, BAT antibodies function by stimulating immune-functioning cells (as disclosed for example in Hardy et al 1994; Hardy et al 1997), whereas chemotherapeutic agents such as 5FU and oxaliplatin act by killing rapidly dividing cells including immune-functioning cells.

As exemplified herein, the combinations according to the present invention are those where use of the chemotherapeutic agents in combination with the humanized antibody of the invention, demonstrate increased or enhanced lymphocyte cell survival. As disclosed in Example 1 and Figures 1-7, lymphocyte cell survival may be conveniently assessed using in vitro assays.

Accordingly, in various embodiments, the chemotherapeutic agent may be selected from an antimetabolite, such as the pyrimidine analog 5-fluorouracil, or cytarabine, or a platinum-based drug, such as oxaliplatin or cisplatin. Further, in various embodiments, the chemotherapeutic agent may be other than an agent selected from a topoisomerase I inhibitor (such as SN-38) and an alkylating agent (such as cyclophosphamide). Antitumor effect induced by the combinations of the invention

includes the prevention, inhibition of the progression of a tumor, reduction of tumor growth and protection against tumor recurrence, including cancerous and noncancerous tumors. The progression of a tumor includes the invasiveness, metastasis, recurrence and increase in size of the tumor. The reduction of tumor growth also includes the 5 destruction or elimination of a tumor leading to complete remission.

In addition, the invention has been further found to be effective for improving tolerability to chemotherapeutic agents. As is known in the art, a major setback for patients undergoing cancer chemotherapy is the appearance of severe and detrimental adverse side effects due to the potent toxicity of most chemotherapeutic agents. As 10 exemplified herein in Example 3, use of a humanized BAT antibody (CT-011) in combination with 5FU at dose-limiting toxicity (DLT) levels, using a sequential administration schedule, results in enhanced survival of mice. These observations support use of humanized BAT antibodies for improving tolerability to chemotherapeutic agents in patients undergoing chemotherapy.

15 The invention further provides a method of enhancing survival in a subject with a tumor, which comprises administration of the humanized antibody of the invention, either on its own, or optionally, combined with the further administration of one or more chemotherapeutic agents. For example, the “cure” effect induced by CT-011 in human cancer patients (Example 8) supports such an antibody monotherapy. This aspect 20 of the invention is particularly advantageous in cases where chemotherapy has failed or where the patient is unable to tolerate chemotherapeutic agents.

25 The invention further provides a method of reducing or preventing recurrence of a tumor, which comprises administration of the humanized antibody of the invention, either on its own, or optionally, combined with the further administration of one or more chemotherapeutic agents. As demonstrated herein in Example 6, combination treatment of experimental animals using the humanized antibody of the invention and chemotherapeutic agents clearly induced a “memory” effect, such that tumor recurrence was inhibited upon re-challenge with the original tumor type.

30 All types of tumors may be treated by the methods of the present invention. The tumors may be solid or non-solid.

Some examples of solid tumors that can be treated with the combination of the present invention include carcinomas, sarcomas, blastomas or gliomas. Some examples

of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, liver tumors, esophageal tumors and gastric tumors. Other examples include Kaposi's 5 sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma. Examples of vascularized skin cancers include squamous cell carcinoma, basal cell carcinoma and skin cancers that can be treated by suppressing the 10 growth of malignant keratinocytes, such as human malignant keratinocytes.

Some examples of non-solid tumors include leukemias, multiple myelomas and lymphomas. Some examples of leukemias include acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), erythrocytic leukemia or monocytic leukemia. Some 15 examples of lymphomas include lymphomas associated with Hodgkin's disease, Non-Hodgkin's disease or mantle cell lymphoma.

Currently preferred types of tumors are selected from the following group: colorectal carcinoma; lung carcinoma including non small lung cancer (NSCLC) and small cell lung cancer (SCLC); breast carcinoma; melanoma; ovarian carcinoma; 20 cervical carcinoma, pancreatic cancer; head and neck carcinoma; gastrointestinal carcinoma; esophageal tumors; hepatocellular carcinoma; multiple myeloma; renal cell carcinoma; prostate tumors; non-Hodgkin's lymphoma; Hodgkin's disease; mantle cell lymphoma; Kaposi's sarcoma; squamous cell carcinoma; basal cell carcinoma; acute myeloid leukemia (AML); chronic myelocytic leukemia (CML); acute lymphocytic 25 leukemia (ALL); chronic lymphocytic leukemia (CLL).

It should be noted that according to the teaching of the present invention, the humanized antibody of the invention may be administered before, during, or after 30 commencing chemotherapy and, optionally, radiation therapy, as well as any combination thereof, i.e. before and during, before and after, during and after, or before, during, and after commencing the chemotherapy and, optionally, the radiation therapy. For example, the antibody of the invention may be administered between 1 and 30 days prior to or after commencing chemotherapy. The antibody may further be administered between courses of chemotherapy.

In the combination therapy methods of the invention, the antibodies may be administered in parallel to the chemotherapy, for example substantially simultaneously or concurrently. Other administration schedules may also be used, for example, overlapping schedules or those which involve alternately, sequentially or successively 5 administering the two types of treatment.

Humanized antibody of the invention

As used herein, the terms "BAT" and a BAT antibody" are used in a broad sense and specifically cover antibodies identical to or based on the murine monoclonal antibody known as mBAT-1, or an antigen binding fragment thereof. The monoclonal 10 antibody mBAT-1 is secreted by the hybridoma cell line deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), under Accession No. 1-1397, as disclosed in U.S. Patent No. 5,897,862. Further "BAT" and a BAT antibody" may refer to an antibody, which recognizes the same antigenic epitope as mBAT-1, for example a chimeric antibody as described in U.S. Patent Application Publication No. 15 2003/0026800. A BAT antibody also includes a humanized antibody, various examples of which are disclosed in WO03/099196 and U.S. Patent Application Publication No. 2008/0025980. The terms "CT-011", "hBAT" and "hBAT-1" are interchangeably used herein to refer to one humanized antibody according to the invention.

In general, the light chain variable region of the humanized monoclonal antibody 20 is characterized by the formula:



wherein each FR is independently a framework region of a human antibody and each CDR is independently a complementarity determining region of the monoclonal mBAT-1 antibody.

25 In general, the heavy chain variable region of the humanized monoclonal antibody is characterized by the formula:



wherein each FR is independently a framework region of a human antibody and each CDR is independently a complementarity determining region of the monoclonal mBAT-30 1 antibody.

In particular embodiments, the FRs are derived from the light chain variable

region of the human TEL9 antibody (SEQ ID NO: 130), or are modified therefrom in certain amino acid residues.

Human TEL-9 antibody was identified in diverse libraries of immunoglobulin heavy (VH) and light (V kappa and V lambda) chain variable (V) genes prepared from 5 peripheral blood lymphocytes of unimmunized donors (Marks et al. J Mol Biol. 1991, 222:581-97). This antibody was shown to bind specifically to the turkey egg-white lysozyme (TEL) antigen.

FR amino acid sequences derived or modified from the light chain variable region of the human TEL9 antibody may be selected from the group consisting of: FR<sub>L1</sub>, 10 [EIVLT QSPSS LSASV GDRVT ITC; SEQ ID NO: 1]; FR<sub>L2</sub>, [W (F or Y) QQKPG KAPKL (W or L) IY; SEQ ID NO: 2]; FR<sub>L3</sub>, [GVPSR FSGSG SGT (D or S) (Y or F) (C or T) LTINS LQPED FATYY C; SEQ ID NO: 3]; and FR<sub>L4</sub>, [FGGGT KLEIK; SEQ ID NO: 4].

In particular embodiments, the FRs are derived from the heavy chain variable 15 region of the human hsighv1295 antibody (SEQ ID NO: 146), or modified therefrom in certain amino acid residues.

Human hsiggvl295 antibody was isolated from stable hybridomas and Epstein-Barr virus-transformed B cell lines from the synovial fluid or peripheral blood of three 20 patients with rheumatoid arthritis and one patient with systemic lupus erythematosus (Fang et al., J Exp Med. 1994, 179:1445-56).

FR amino acid sequences derived or modified from the heavy chain variable region of the human hsighv1295 antibody may be selected from the group consisting of: FR<sub>H1</sub>, [Q (I or V) QLV QSGSE LKKPG ASVKI SCKAS GY (T or S) F (T or S); SEQ ID NO: 5]; FR<sub>H2</sub>, [WV (R OR K) QAPGQ GL (Q or K) WMG; SEQ ID NO: 6]; FR<sub>H3</sub>, 25 [RF (V or A) FSLDT SV (N or S) TAYLQ ITSL (T or N) AEDTG MYFC (V or A) (R or K); SEQ ID NO: 7]; and FR<sub>H4</sub>, [WGQGT LVTVS S; SEQ ID NO: 8].

According to various embodiments, the light chain variable region comprises at 30 least one amino acid sequence selected from the group consisting of: CDR<sub>L1</sub> [SARSS VSYM; SEQ ID NO: 9]; CDR<sub>L2</sub> [RTSNL AS; SEQ ID NO: 10]; CDR<sub>L3</sub> [QQRSS FPLT; SEQ ID NO: 11], wherein the CDRs are derived from the murine BAT-1 antibody and the subscripts "L" and "H" refer to light and heavy chain regions, respectively.

According to various embodiments, the heavy chain variable region comprises at least one amino acid sequence selected from the group consisting of: CDR<sub>H1</sub> [NYGMN; SEQ ID NO: 12]; CDR<sub>H2</sub> [WINTD SGEST YAEEF KG; SEQ ID NO: 13]; CDR<sub>H3</sub> [VGYDA LDY; SEQ ID NO: 14].

5 According to various embodiments, the humanized antibody comprises: a light chain variable region selected from the group consisting of: BATR<sub>kA</sub> (SEQ ID NO: 15), BATR<sub>kB</sub> (SEQ ID NO: 16), BATR<sub>kC</sub> (SEQ ID NO: 17), and BATR<sub>kD</sub> (SEQ ID NO: 18); and

10 a heavy chain variable region selected from the group consisting of: A (SEQ ID NO: 20), BATR<sub>Hb</sub> (SEQ ID NO: 21), BATR<sub>Hc</sub> (SEQ ID NO: 22), BATR<sub>Hd</sub> (SEQ ID NO: 23) and BATR<sub>He</sub> (SEQ ID NO: 24).

According to yet other embodiments, the humanized antibody comprises variable regions selected from the group consisting of: BATR<sub>H</sub><sub>A</sub>/BATR<sub>kA</sub> (SEQ ID NO: 20/SEQ ID NO: 15), BATR<sub>Hb</sub>/BATR<sub>kA</sub> (SEQ ID NO: 21/SEQ ID NO: 15),  
15 BATR<sub>Hb</sub>/BATR<sub>kB</sub> (SEQ ID NO: 21/SEQ ID NO: 16), BATR<sub>Hc</sub>/BATR<sub>kB</sub> (SEQ ID NO: 22/SEQ ID NO: 16), BATR<sub>Hb</sub>/BATR<sub>kD</sub> (SEQ ID NO: 21/SEQ ID NO: 18), and BATR<sub>Hc</sub>/BATR<sub>kD</sub> (SEQ ID NO: 22/SEQ ID NO: 18).

According to various preferred embodiments, the humanized monoclonal antibody has variable regions corresponding to BATR<sub>H</sub><sub>C</sub>/BATR<sub>kD</sub> (SEQ ID NO: 22/SEQ ID NO: 18).

In one embodiment, the humanized BAT antibody has a heavy chain variable region as set forth in SEQ ID NO: 22 which may be encoded by the polynucleotide sequence set forth in SEQ ID NO: 90.

25 In one embodiment, the humanized antibody has a light chain variable region as set forth in SEQ ID NO: 18 which may be encoded by the polynucleotide sequence set forth in SEQ ID NO: 89. Amino acid and nucleotide sequences of humanized antibodies suitable for use in the invention are disclosed in U.S. Patent Application Publication No. 2008/0025980. Human antibody framework regions of heavy chain variable regions and light chain variable regions suitable for use in the invention include for example SEQ 30 ID NOS: 111-128 and SEQ ID NOS: 130-144, respectively.

Chemotherapy

Chemotherapy drugs are divided into several groups based on their effect on cancer cells, the cellular activities or processes the drug interferes with, or the specific phases of the cell cycle the drug affects. Accordingly, chemotherapy drugs fall in one of the following categories: alkylating agents, nitrosoureas, antimetabolites, anthracyclines, topoisomerase I and II inhibitors, mitotic inhibitors, *inter alia* platinum based drugs, steroids and anti-angiogenic agents.

Antimetabolites, also termed “nucleoside analogs”, replace natural substances as building blocks in DNA molecules, thereby altering the function of enzymes required for cell metabolism and protein synthesis. In the event that they mimic nutrients required for cell growth, the cells eventually undergo lysis. If a nucleoside is replaced with a non-functional nucleoside analog, the latter is incorporated into DNA and RNA, finally inducing cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. Antimetabolites are cell-cycle specific and are most effective during the S-phase of cell division as they primarily act upon cells undergoing synthesis of new DNA for formation of new cells. The toxicities associated with these drugs are seen in cells that are growing and dividing quickly. Examples of antimetabolites include purine antagonists, pyrimidine antagonists, and folate antagonists. These agents damage cells during the S phase and are commonly used to treat leukemias, tumors of the breast, ovary, and the gastrointestinal tract, as well as other cancers. Specific examples of antimetabolites include 5-fluorouracil (also known as 5FU), capecitabine, 6-mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine and pemetrexed.

Platinum-based chemotherapeutic drugs crosslink DNA in several different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair proves impossible. Most notable among the DNA changes are the 1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand d(ApG) adducts. 1,3-intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision repair (NER). Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to the activity of platinum-based drugs. Interaction with cellular proteins, particularly HMG domain proteins, has also been advanced as a mechanism of interfering with mitosis, although this is probably not its primary method of action.

Platinum-based chemotherapeutic drugs include cisplatin (also known as cisplatin or *cis*-diamminedichloroplatinum II (CDDP), carboplatin and oxaliplatin. Cisplatin is frequently designated as an alkylating agent, though it has no alkyl group and cannot carry out alkylating reactions. It is correctly classified as alkylating-like. Platinum-based 5 chemotherapeutic drugs are used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors.

Mitotic inhibitors interfere with cell division. The most known chemotherapeutic agent in this category is paclitaxel (also known as Taxol®, "plant alkaloid", "taxane" 10 and an "antimicrotubule agent"). Together with docetaxel, it forms the drug category of the taxanes. However, other mitotic inhibitors are known, including, but not limited to etoposide, vinblastine and vincristine. Paclitaxel acts by interfering with normal microtubule growth during cell division by arrests their function; it hyper-stabilizes 15 their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the  $\beta$  subunit of tubulin, the "building block" of microtubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This 20 adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a mechanism to transport other cellular components. For example, during mitosis, microtubules position the chromosomes all through their replication and subsequent separation into the two daughter-cell nuclei. Furthermore, paclitaxel induces programmed cell death (apoptosis) 25 in cancer cells by binding to the apoptosis stopping protein Bcl-2 (B-cell leukemia 2) and thus arresting its function.

Another group of DNA-interacting drugs widely used in anti-cancer chemotherapy 25 is the group of anthracycline antibiotics which includes, *inter alia*, daunorubicin, doxorubicin (also known as Adriamycin® and doxorubicin hydrochloride), respinomycin D and idarubicin. These drugs interact with DNA by intercalation and inhibition of macromolecular biosynthesis thereby inhibiting the progression of the 30 enzyme topoisomerase II, which unwinds DNA for transcription. They stabilize the topoisomerase II complex after it has broken the DNA chain for replication, preventing

the DNA double helix from being resealed and thereby stopping the process of replication. It is commonly used in the treatment of a wide range of cancers.

Alkylating antineoplastic agents directly attack DNA. They attach an alkyl group to DNA, cross-linking guanine nucleobases in DNA double-helix strands. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically. Cyclophosphamide is an alkylating agent, however, it is a highly potent immunosuppressive substance.

Topoisomerase I and II inhibitors interfere with the enzymatic activity of topoisomerase I and 2, respectively, eventually leading to inhibition of both DNA replication and transcription. Examples of topoisomerase I inhibitors include topotecan and irinotecan. Irinotecan, is a prodrug converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is also classified as an S-phase-specific agent. Examples of topoisomerase II inhibitors include etoposide and teniposide.

Anti-angiogenic agents interfere with the generation of new blood vessels, eventually leading to the "starvation" of tumors. Non-limiting examples of anti-angiogenic agents include the monoclonal antibody bevacizumab, dopamine and tetrathiomolybdate.

Vascular endothelial growth factor (VEGF) is a 32-42 kDa dimeric glycoprotein which mediates vasodilatation, increased vascular permeability and endothelial cell mitogenesis. Differential exon splicing of the VEGF gene results in three main mRNA species which code for three secreted isoforms (subscripts denote numbers of amino acids): VEGF189, VEGF165, and VEGF121. A number of minor splice variants have also been described (VEGF206, VEGF183, VEGF145 and VEGF148). Variants of VEGF polypeptides and their use in cancer therapy is disclosed for example, in

WO/2003/012105.

### Radiation

The source of radiation that may be used in combination with the humanized antibody of the invention and the chemotherapeutic agent(s) can be either external or internal to the patient being treated. When the source is external to the patient, the therapy is known as external beam radiation therapy (EBRT). When the source of radiation is internal to the patient, the treatment is called brachytherapy (BT).

Radiation is administered in accordance with well known standard techniques using standard equipment manufactured for this purpose, such as AECL Theratron and Varian Clinac.

The distance between the source of the external radiation and the point of entry into the patient may be any distance that represents an acceptable balance between killing target cells and minimizing side effects. Typically, the source of the external radiation is between 70 and 100 cm from the point of entry into the patient.

Brachytherapy is generally carried out by placing the source of radiation in the patient. Typically, the source of radiation is placed approximately 0-3 cm from the tissue being treated. Known techniques include interstitial, intercavitory, and surface brachytherapy. The radioactive seeds can be implanted permanently or temporarily. Some typical radioactive atoms that have been used in permanent implants include iodine-125 and radon. Some typical radioactive atoms that have been used in temporary implants include radium, cesium-137, and iridium-192. Some additional radioactive atoms that have been used in brachytherapy include americium-241 and gold-198.

The dose of radiation depends on numerous factors as is well known in the art. Such factors include the organ being treated, the healthy organs in the path of the radiation that might inadvertently be adversely affected, the tolerance of the patient for radiation therapy, and the area of the body in need of treatment. The dose will typically be between 1 and 100 Gy, and more particularly between 2 and 80 Gy. Some doses that have been reported include 35 Gy to the spinal cord, 15 Gy to the kidneys, 20 Gy to the liver, and 65-80 Gy to the prostate. It should be emphasized, however, that the invention is not limited to any particular dose. The dose will be determined by the treating physician in accordance with the particular factors in a given situation, including the factors mentioned above.

The dose of radiation for brachytherapy can be the same as that mentioned above for external beam radiation therapy. In addition to the factors mentioned above for

determining the dose of external beam radiation therapy, the nature of the radioactive atom used is also taken into account in determining the dose of brachytherapy.

Compositions, administration and dosages

For use in the methods of the invention, the humanized antibody may be  
5 formulated in a conventional manner using one or more pharmaceutically acceptable  
carriers, stabilizers or excipients (vehicles) to form a pharmaceutical composition as is  
known in the art, in particular with respect to protein active agents. Carrier(s) are  
“acceptable” in the sense of being compatible with the other ingredients of the  
composition and not deleterious to the recipient thereof. Suitable carriers typically  
10 include physiological saline or ethanol polyols such as glycerol or propylene glycol.

The antibody may be formulated as neutral or salt forms. Pharmaceutically  
acceptable salts include the acid addition salts (formed with free amino groups) and  
which are formed with inorganic acids such as hydrochloric or phosphoric acids, or  
such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free  
15 carboxyl groups may also be derived from inorganic bases such as sodium, potassium,  
ammonium, calcium, or ferric hydroxides, and organic bases as isopropylamine,  
trimethylamine, 2-ethylamino ethanol, histidine and procaine.

The compositions may be suitably formulated for intravenous intramuscular,  
subcutaneous, or intraperitoneal administration and conveniently comprise sterile  
20 aqueous solutions of the antibody, which are preferably isotonic with the blood of the  
recipient. Such formulations are typically prepared by dissolving solid active ingredient  
in water containing physiologically compatible substances such as sodium chloride,  
glycine, and the like, and having a buffered pH compatible with physiological  
conditions to produce an aqueous solution, and rendering said solution sterile. These  
25 may be prepared in unit or multi-dose containers, for example, sealed ampoules or vials.

The compositions may incorporate a stabilizer, such as for example polyethylene  
glycol, proteins, saccharides (for example trehalose), amino acids, inorganic acids and  
admixtures thereof. Stabilizers are used in aqueous solutions at the appropriate  
concentration and pH. The pH of the aqueous solution is adjusted to be within the range  
30 of 5.0-9.0, preferably within the range of 6-8. In formulating the antibody, anti-  
adsorption agent may be used. Other suitable excipients may typically include an  
antioxidant such as ascorbic acid.

The compositions may be formulated as controlled release preparations which may be achieved through the use of polymer to complex or absorb the proteins. Appropriate polymers for controlled release formulations include for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, and methylcellulose.

5 Another possible method for controlled release is to incorporate the antibody into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by

10 interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.

When oral preparations are desired, the compositions may be combined with carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic.

The humanized antibody of the invention is preferably administered parenterally, generally by intravenous infusion. Administration may also be by intraperitoneal, oral, subcutaneous, or intramuscular routes. Antibodies are generally administered in the range of about 0.1 to about 20 mg/kg of patient weight, commonly about 0.5 to about 10 mg/kg, and often about 1 to about 5 mg/kg. In this regard, it is preferred to use antibodies having a circulating half-life of at least 12 hours, preferably at least 4 days, more preferably up to 21 days. Chimeric and humanized antibodies are expected to have circulatory half-lives of up to four and up to 14-21 days, respectively.

25 In some cases it may be advantageous to administer a large loading dose followed by periodic (e.g., weekly) maintenance doses over the treatment period. Antibodies can also be delivered by slow-release delivery systems, pumps, and other known delivery systems for continuous infusion. Dosing regimens may be varied to provide the desired circulating levels of a particular antibody based on its pharmacokinetics. Thus, doses

30 will be calculated so that the desired circulating level of therapeutic agent is maintained.

Typically, the effective dose will be determined by the activity of the therapeutic combination and the condition of the subject, as well as the body weight or surface area of the subject to be treated. The size of the dose and the dosing regimen also will be

determined by the existence, nature, and extent of any adverse side effects that accompany the administration of each agent in the combination of the invention in a particular subject. In determining the effective amount of the therapeutic composition to be administered, the physician needs to evaluate *inter alia* circulating plasma levels, 5 toxicity, and progression of the disease.

In various embodiments of the combination methods of the invention, the humanized antibody and the chemotherapeutic agent may be administered according to any of a number of treatment schedules, also referred to "dosing schedules" and "administration regimens", referring to the frequency of administration and order of administration of 10 each active agent. For example, the humanized antibody and the chemotherapeutic agent may be administered substantially simultaneously i.e. at the same time, using for example a combined dosage form or separate dosage forms. This form of administration may also be referred to as "concomitant" administration. Concurrent administration refers to administration of the active agents within the same general time period, for 15 example on the same day(s) but not necessarily at the same time. For example, one active agent may require administration with food, while the other requires administration in the semi-fasting state. Alternate administration includes administration of one agent during a particular time period, for example over the course of a few days or a week, followed by administration of the other agent during a subsequent identical 20 period of time, and then repeating the pattern for one or more cycles. Sequential or successive administration includes administration of one agent during a first time period, using one or more doses, followed by administration of the other agent during a second time period using one or more doses. An overlapping schedule may also be employed, which includes administration of the active agents on different days over the 25 treatment period, not necessarily according to a regular sequence. Variations on these general guidelines may also be employed, according to the agents used and the condition of the subject.

In some particular combinations, it may be advantageous to use a specific sequence of administration e.g. one agent prior to the other. For example, as 30 demonstrated herein (Figure 5) dacarbazine adversely affects the activity of the antibody when given concomitantly but not when added 24 hours after the humanized antibody.

Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

## 5 EXAMPLES

### Example 1. In vitro functional assay

The functional assay is based on the ability of hBAT-1 to enhance the survival of murine and human lymphocytes in culture. In the present Example, the effect of hBAT-1 on enhanced survival of lymphocytes alone and in combination with 10 chemotherapeutic drugs was evaluated and expressed by % difference in cell survival or by the Area Under the dose response Curve (AUC, expressed in % difference X  $\mu$ g/ml). The chemotherapeutic agent was applied concomitantly or 24 hours after hBAT-1 treatment at the indicated concentrations. Chemotherapeutic agents tested in the functional assay included 5FU (Figs. 1,2 and 7), SN-38, an active derivative of 15 irinotecan (Figs. 3 and 4), cisplatin, oxaliplatin, Taxol (paclitaxel) and dacarbazine (Fig. 5 and 7), cytarabine, cyclophosphamide and doxorubicin (Fig. 6).

The results indicate that specific agents (e.g. 5FU, cisplatin, oxaliplatin, paclitaxel and cytarabine) do not adversely affect the activity of hBAT-1 in murine lymphocytes. Moreover, when given concomitantly with (cisplatin), or sequentially (5FU and 20 paclitaxel) with hBAT-1, a synergistic effect is observed, expressed by 20% to 30% enhancement in activity values (% difference in cell survival and AUC). Use of a chemotherapeutic agent alone has no activity in increasing lymphocyte cell survival in this functional assay (Fig. 1C). Synergistic results were obtained with isolated human CD4+ lymphocytes, demonstrating that sequential treatment of 5FU or cisplatin in 25 combination with hBAT resulted in activity (% difference in cell survival) that is 2 fold higher than the activity of the antibody alone (Fig. 7). The results also suggest that certain chemotherapeutic agents (e.g. SN-38; cyclophosphamide) may not be suitable for use in combination with humanized BAT antibodies, since they do not enhance cell survival when given in combination with hBAT-1 in murine lymphocyte culture. . In 30 addition, certain chemotherapeutic agents (e.g. dacarbazine) may be suitable only when used in a sequential administration schedule (Fig. 3-5).

Example 2. Combination therapy for colorectal cancer tumors

Colorectal carcinoma tumors (CT26 tumors) were induced by S.C. injection of CT26 cells,  $10^6$  cells/mouse (n=6). Day of injection is referred herein as day 0. 5-FU, 20 mg/kg, was administered I.P. on days 6-9, 15-17, 22-24 and 29-31, 36-38 and 43-45. 5 hBAT-1, 10 mg/mouse, was administered I.V. on days 10, 18, 25, 32 and 39 (Fig. 8-10). A case of relapse after complete remission (observed only in the combination therapy group) was further treated with 5FU at 20 mg/kg, on days 73-74, 77-80, 85-87, 92-93 and hBAT-1, 10 mg/mouse, administered I.V. on days 81 and 88.

In a follow up study on tumor size after a single cycle of treatment, tumor volume 10 was measured every other day on days 4 to 16 post tumor inoculation. The results indicate that the combined therapy with 5FU is advantageous over therapy with either 5FU or hBAT-1 alone (Fig. 8).

In a follow up study on tumor size after 3 alternate cycles of treatment, tumor volume was measured every other day on days 4 to 28. The results indicate that the 15 combination therapy of hBAT-1 antibody with 5FU is not only advantageous over 5FU monotherapy but the increase in activity is synergistic (Fig.9).

In a follow up study on overall survival, percentage survival was monitored and is 20 presented in Fig.10 from day 28 and onwards. The results clearly show that in mice treated with the combination therapy, the percent of survival is significantly higher than in mice treated with either hBAT-1 or 5FU monotherapies, leading to durable complete remission in approximately 17% of the mice.

Example 3. Combination therapy for melanoma

Mice (n=7) were inoculated subcutaneously with B16 melanoma cells at  $5 \times 10^5$  25 cells/mouse. Inoculation day is referred herein as day 0. 5-FU was administered intraperitoneally at 50 mg/kg on days 1-4 and 7-8. In the combination therapy group, a single dose of 10 mg/mouse of hBAT-1 was injected intravenously on day 10.

Percentage survival was monitored beginning at day 8. In mice treated with the combination therapy the percent of survival was significantly higher than in mice treated with high dosage of 5FU (Fig. 11).

30 Stated otherwise, combination treatment, using a sequential administration schedule in which the humanized antibody was administered after 9 daily cycles of 5FU

at dose-limiting toxicity (DLT) levels (50mg/kg/day), resulted in enhanced survival of mice in an experimental melanoma model. The results clearly suggest that the combination therapy improves tolerability to DLT levels of 5-FU.

Example 4. Combination therapy with irinotecan (1)

5 Colorectal carcinoma tumors (CT26 tumors) were induced by S.C. injection of CT26 cells,  $10^6$  cells/mouse (n=6). Day of injection is referred herein as day 0. Irinotecan, 100 mg/kg, was administered I.P. on days 7 and 15. hBAT-1, 10 mg/mouse, was administered I.V. on day 10 (Fig. 12).

10 In a follow up study on tumor size after a single cycle of treatment, tumor volume was measured daily on days 4 to 18. The results indicate that the combination therapy of hBAT-1 antibody with irinotecan is as effective as monotherapy with irinotecan, but less effective than hBAT-1 monotherapy (Fig. 12).

Example 5. Combination therapy with irinotecan (2)

15 Colorectal carcinoma tumors (CT26 tumors) were induced by S.C. injection of CT26 cells,  $10^6$  cells/mouse (n=6). Day of injection is referred herein as day 0. Irinotecan, 100 mg/kg, was administered I.P. on days 7 and 15. hBAT-1, 10 mg/mouse, was administered I.V. on day 10 (Fig. 13).

20 Percentage survival was monitored beginning at day 16. The results show that in mice treated with the combination therapy, the percent of survival is comparable to that of mice treated with irinotecan monotherapy, but lower than in mice treated with hBAT-1 monotherapy (Fig. 13).

Example 6. Combination therapy with oxaliplatin

25 Colorectal carcinoma tumors (CT26 tumors) were induced by S.C. injection of CT26 cells,  $10^6$  cells/mouse (n=6). Day of injection is referred herein as day 0. Oxaliplatin, 1 mg/kg, was administered I.P. on days 4, 7-10, 14-17, 22-24 and 29-31. hBAT-1, 10 mg/mouse, was administered I.V. on days 11, 18, 25 and 32 (Fig. 14-15).

30 In a follow up study on tumor size, tumor volume was measured every other day on days 4 to 23 post tumor inoculation. The results indicate that the combined therapy with oxaliplatin is advantageous over therapy with oxaliplatin alone (Fig. 14).

In a follow up on overall survival, percentage survival was monitored beginning at day 15. The results clearly show that in mice treated with the combination therapy, the

percent of survival is significantly higher than in mice treated with oxaliplatin monotherapy leading to durable complete remission in approximately 20% of the mice (Fig. 15).

Colorectal carcinoma tumors (CT26 tumors) were re-induced by S.C. injection of 5 CT26 cells,  $10^6$  cells/mouse in mice that had been cured for 2 or 5 months by hBAT-1 and oxaliplatin combination therapy (n=3). Colorectal carcinoma tumors were newly induced in control naïve mice at a similar age (n=6). Day of injection is referred herein as day 0 (Fig. 16). Before the re-induction (re-challenge) of CRC, treatment-experienced mice were evaluated for complete clearance of serum levels of hBAT-1 by 10 specific ELISA.

In a follow up study on tumor size, tumor volume was measured every other day and is presented as a follow up from days 4 to 23 post tumor inoculation. The results indicate that in mice previously cured by hBAT-1 and oxaliplatin combination therapy, no tumor was observed during the 2 months follow up, whilst in the control group, the 15 tumor developed within days in all mice (Fig. 16A).

In a follow up study on overall survival, percentage survival was monitored beginning at day 21 post tumor re-inoculation. The results clearly show that the mice which were newly introduced with the tumor (CRC) died within 35 days, whilst mice previously cured by hBAT-1 and oxaliplatin combination therapy were protected from 20 tumor growth, tumor recurrence and death for more than the 72 days of the study follow up (Fig. 16B).

Breast adenocarcinoma tumors (4T1 tumors) were re-induced by S.C. injection of 4T1 cells,  $10^6$  cells/mouse in mice previously cured by hBAT and oxaliplatin and 25 protected against re-challenge of CRC for approximately 3 months (Mice described in Fig. 16, n=2). In these mice, the tumor was injected S.C. at a different site than that of the 1<sup>st</sup> CRC and 2<sup>nd</sup> CRC injection sites (re-challenged CRC tumors). Breast adenocarcinoma tumors were also introduced in naïve mice at a similar age (n=6). Day of injection is referred herein as day 0 (Fig. 17).

In a follow up study on tumor size, tumor volume was measured every other day 30 and is presented from days 3 to 21 post tumor inoculation. The results indicate that the breast adenocarcinoma tumors progressed in both mice groups (Fig. 17A). These results clearly show that mice that have acquired full protection against colorectal carcinoma

following combination therapy of hBAT-1 and oxaliplatin (Fig. 16A), were not as protected against breast carcinoma (Fig. 17A).

In a follow up study on overall survival, percentage survival was monitored beginning at day 21 post tumor re-inoculation. The results clearly show that the mice in 5 both groups died within 28 to 35 days from breast carcinoma, indicating that mice exhibiting long term protection against CRC recurrence (re-challenge) were not fully protected against a different type of tumor e.g. breast carcinoma. Since all previously treated mice were tested for the complete elimination of circulating serum levels of the antibody of the invention, it appears that the acquired tumor specific protection against 10 colorectal carcinoma was not a result of an active therapy but rather of an immunological memory response induced following previous treatment with the antibody of the invention and oxaliplatin.

Overall, combination therapy of the antibody of the invention and specific 15 chemotherapeutic agents, such as 5FU or oxaliplatin, when administered according to an alternating schedule, results in enhanced antitumor activity, as evaluated by the reduction in tumor growth and the enhancement in survival of tumor bearing mice. Unexpectedly, mice in the combination therapy groups have reached durable complete remission and in the case of oxaliplatin even acquired memory protection against tumor recurrence, as evaluated by re-challenge with the specific tumor (CRC).

20 Example 7. Effect of CT-011 on human effector/memory T cells

The activity of hBAT-1 (CT-011) was assessed in an assay based on viability of 25 human lymphocytes. Effector/memory CD4+CD45RO+ and naïve CD4+CD45RO- lymphocytes were treated with hBAT at 1ug/ml, followed by incubation for 72 and 96 hours. The results are expressed as % difference in cell survival (Figure 18).

The results clearly indicate that CT-011 has a significant effect in enhancing the 30 survival of human effector/memory CD4+CD45RO+ lymphocytes, but not that of naïve CD4+CD45RO- lymphocytes. The demonstrated activity of CT-011 in promoting the viability of memory precursor cells is consistent with the in vivo results demonstrating that CT-011 has activity in inducing immunological memory against tumor recurrence.

30

Example 8. Phase I clinical trial of humanized monoclonal antibody CT-011

### Introduction

The objectives of this study were to assess the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD) and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematological malignancies. A full 5 description of the study is provided in Berger et al. Clin. Cancer Res. 2008;14(10) May 15, 2008.

### Patients And Methods

Entrance criteria for the study required that enrolled patients had to have one of the following hematological malignancies: acute myeloid leukemia (AML), chronic 10 lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), or multiple myeloma (MM) at an advanced stage of their disease and following chemotherapy and/or stem cell transplantation (SCT). Patients were eligible for this study provided that they met the criteria as set out in Berger et al.

Importantly, the criteria included: At least 4 weeks from stem cell transplantation 15 (SCT) or 1 week from donor lymphocyte infusion (DLI); Life expectancy >3 months; Patients who were either receiving or did not recover from the effect of therapies having immune suppressive effects, or who were suffering from an autoimmune disorder were to be excluded. The exception to this was hydroxyurea treatment of AML patients, which was allowed to proceed. The use of concomitant anti-cancer treatment 20 (chemotherapy and immunotherapy) was prohibited and accordingly was to be stopped at least 4 weeks prior to CT-011 administration.

The study enrolled a total of 17 patients. One patient who was enrolled at the lowest dose level (0.2 mg/kg) was re-enrolled 5 months after the first administration at a higher dose level (3.0 mg/kg) as a compassionate treatment for a total of 18 25 administered treatments. The total amount of CT-011 was determined based on the planned dosing (mg/kg base) and body weight. The infusion was carried out in a stepwise manner increasing the rate from 50 mL/hr to 100 mL/hr, and all patients received pre-medication prior to infusion consisting of a pain relief medication (paracetamol), corticosteroid (hydrocortisone 100 mg) and an antihistamine (phenergan). 30 The starting dose was 0.2 mg/kg, which was several ten-fold lower than the highest dose tested in toxicology studies conducted in non-human primates and mice on a human-equivalent-dose (HED) base. The further dose levels were 0.6 mg/kg, 1.5 mg/kg,

3 mg/kg, and 6 mg/kg. Escalation from one dose level to the next was allowed after all patients at the previous level were evaluated for at least 7 days following the dose administration.

5       Toxicity was evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE V2) and by its intensity (i.e., mild, moderate, severe). DLT was defined as that dose which induces any Grade 3 or 4 toxicity in one or more patients, or any Grade 2 toxicity in at least 2/3 or 3/6 patients. Adverse events not judged to be related to CT-011 were not considered as toxicity in terms of these dose escalation and MTD rules.

10       Subsequent to drug administration, patients were monitored for safety, including adverse events and clinical and laboratory responses at 24 hours, 48 hours, and on days 7, 14, and 21.

15       Sample collection, parameters used to assess clinical responses, pharmacokinetic analysis, immune system activation and statistical analysis are as described in Berger et al, 2008.

### Results

20       The main characteristics of the enrolled patients (n=17) are listed in Table 1. Patient 003, initially treated at 0.2 mg/kg, requested a repeat compassionate treatment and was treated again at 3 mg/kg. Due to the 5 month interval between the first and second treatment, the different treatments were analyzed as separate individuals. Therefore, the number of CT-011 administrations used for the analyses was 18.

25

30

**Table 1. Patient Characteristics**

ID	Dose (mg/kg)	Age	Gender	Disease	Classification/Type	Stage	ECOG	Last Treatment prior to CT-011 therapy
001	0.2	64	F	AML	M4- Myelomonocytic	NR	2	Allogeneic SCT
002	0.2	62	F	NHL	ALCL	III	3	Irradiation
003	0.2	73	F	AML	M4- Myelomonocytic	NR	0	G-CSF, Erythropoietin, Blood transfusion
004	0.6	60	F	NHL	DLBCL	IV	1	Irradiation
005	0.6	52	M	CLL		C	2	Irradiation
006	0.6	26	F	HD		IVB	0	Irradiation
007	1.5	58	F	CLL		C	2	Mitoxantrone
008	1.5	68	F	CLL		A	1	Chlorambucil
009	1.5	53	M	AML	M2- Myelocytic	NR	1	Allogeneic SCT
010	3.0	33	F	AML	M4- Myelomonocytic	NR	1	Allogeneic SCT
011	3.0	20	M	AML	M1- Myelocytic	NR	0	Mitoxantrone+cytosar
012	3.0	78	M	MDS	CMMI	NR	2	Hydroxyurea, Thalidomide
013	6.0	65	M	AML	M4- Myelomonocytic	NR	2	Allogeneic SCT
014	3.0	40	F	NHL	DLBCL	II	4	Autologous SCT
015	3.0	56	F	NHL	Follicular Lymphoma	III	1	No therapy

ID	Dose (mg/kg)	Age	Gender	Disease	Classification/ Type	Stage	ECOG	Last Treatment prior to CT-011 therapy
016	3.0	73	F	AML	M4- Myelomonocytic	NR	1	CT-011
017	6.0	78	M	MM	IgG; Kappa	IA	1	No therapy
018	6.0	72	F	AML	M4- Myelomonocytic	NR	1	Hydroxyurea

Abbreviations: ALCL, Acute lymphocytic cell lymphoma, CMML, Chronic myelomonocytic leukemia, DLBCL, Diffuse large B cell lymphoma, FAB classification-French, American and British, M1, M2, M4 according to the FAB classification, NR, Non 5 relevant, SCT, Stem cell transplantation.

No DLT was reached in the study. CT-011 was found to be safe and well tolerated with no treatment-related toxicities. No single dose MTD was found in this study.

During the study, 61% (11 of 18) of patients reported adverse events (AE), the 10 most frequent AE observed was diarrhea, but it was concluded that it was not associated with CT-011 treatment.

Four serious adverse events occurred, all of which resulted in death and occurred in AML patients. Clinical analysis concluded that all of these patients died from fulminate resistant leukemia and none of these deaths was considered to be related to 15 study drug.

Over the 21 days of the study no change in the average percentage of blasts in the peripheral blood of AML patients were observed with the exclusion of one AML patient (reduction in peripheral blasts from 50% to 5%). Additionally, there were no changes in disease parameters during the 21 days of the study in 2 CLL patients, 4 NHL patients 20 and in one Multiple Myeloma patient.

The cumulative survival of all patients (n=18) at 21 days was 76%, with a 95% confidence interval of 48%–90%. No difference in mean survival time across the dose groups was noted.

Patients were followed for survival beyond the 21 days of the study. The mean survival time in the study was  $25 \pm 27$  weeks, ranging from 1.7 to over 77 weeks. This follow-up suggested that 6 patients exhibited apparent response to treatment with extended survival averaging at least 60 weeks. The 6 "responder" patients are 5 represented in Table 2. There was one complete remission in patient #015 that received the fourth dose level of 3.0mg/kg. This patient was diagnosed with stage III follicular lymphoma involving nodes below and above the diaphragm. The patient did not receive any prior treatment for her disease. In a CT scan performed during a periodic check 10 month post CT-011 treatment complete elimination of tumor masses was observed.

10 Interestingly, the patient did not receive any further treatment during the period lapsed between CT-011 treatment and the 10 month check. The patient has demonstrated a sustained remission 68 weeks following CT-011 treatment. One minimal response was observed in an AML patient receiving CT-011 at 0.2 and 3 mg/kg). The patient progressed 61 weeks after receiving CT-011. Four patients have shown stable disease:

15 one with HD receiving CT-011 at 0.6 mg/kg had a stable disease for 35 weeks. Two patients with CLL receiving the antibody at 0.6 mg/kg and at 1.5 mg/kg were stable for 36 weeks and over 78 weeks, respectively. A MM patient receiving CT-011 at 6.0 mg/kg showed stable disease for over 60 weeks.

**Table 2.** Clinical responses during the study follow-up period.

Disease (Pt. No.)	Dose (mg/kg)	Observations	Overall Survival (Weeks)	Comments
NHL (015)	3.0	CR	>68	Follicular B cell lymphoma with large tumor masses at nodes above and below the diaphragm and at the mediastinum No previous treatment Elimination of tumor masses by CT scan noted 10 months post CT-011 treatment
CLL (008)	1.5	SD	>78	Binet stage A with bone marrow involvement and at ECOG 3 Received Leukeran about 2 years prior to CT-011 Stable for >17 months
CLL (005)	0.6	SD	36	Binet stage C with large tumor masses not responding to chemo- or radiotherapy and allogeneic SCT Stable for 8 months prior to deterioration

Disease (Pt. No.)	Dose (mg/kg)	Observations	Overall Survival (Weeks)	Comments
HD (006)	0.6	SD	35	Classification IV B; Resistant disease, failed autologous SCT and radiotherapy Stable for 8 months prior to deterioration
MM (017)	6.0	SD	>60	Common type, IgG kappa at Stage IA and ECOG 1 who did not receive any previous treatment for his disease Stable for >13 months
AML (003/016)	0.2/3.0	MR	61	Second dose 5 months post first dose. Platelet transfusion-independent for 9 months. Reduction in peripheral blasts (50% to 5%) on first dose

CR = complete response; SD = stable disease; MR = minimal response.

### Discussion and Conclusion

The cumulative survival of all patients at 21 days was 76%, and follow up beyond the 21 days of the study revealed mean survival of 25 weeks. Given that most of the 5 patients were at an advanced stage of their disease, it was surprisingly and unexpectedly found that 6 patients exhibited clinical benefit with extended survival averaging 60 weeks.

The median  $t_{1/2}$  of CT-011 ranged from 217 hr to 410 hr (9 to 17 days), consistent with observations with other monoclonal antibodies in humans. Interestingly, the 10 median  $t_{1/2}$  for the 6 patients with apparent clinical response (Table 2) was somewhat higher than that of the rest of the patients. Taking into account the duration of the response with an average of 60 weeks in these 6 patients and the pharmacokinetics of the antibody with a highest half life of 410 hours, it appears that in some patients, tumor-specific immunological memory is induced, leading to durable anti-tumor 15 immune response long after the antibody has been eliminated from the blood.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such 20 adaptations and modifications should and are intended to be comprehended within the

meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.

## CLAIMS

1. A method of treating a tumor or enhancing survival of a subject having a tumor, the method comprising (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a functional fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent wherein said humanized antibody and chemotherapeutic agent are administered simultaneously, concurrently or according to an overlapping schedule; thereby treating the tumor or enhancing survival of the subject having the tumor.
2. A method of improving tolerability to dose-limiting toxicity levels of at least one chemotherapeutic agent, the method comprising administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a functional fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; wherein the subject is undergoing chemotherapy with at least one chemotherapeutic agent and the humanized antibody and chemotherapeutic agent are administered simultaneously, concurrently or according to an overlapping schedule; thereby improving tolerability to dose-limiting toxicity levels of said at least one chemotherapeutic agent.
3. The method according to claim 1 or claim 2, wherein the humanized antibody comprises: a light chain variable region selected from the group consisting of: BATR $\kappa$ A (SEQ ID NO: 15), BATR $\kappa$ B (SEQ ID NO: 16), BATR $\kappa$ C (SEQ ID NO: 17), and BATR $\kappa$ D (SEQ ID NO: 18), and a heavy chain variable region selected from the group consisting of: BATR $\alpha$ A (SEQ ID NO: 20), BATR $\alpha$ B (SEQ ID NO: 21), BATR $\alpha$ C (SEQ ID NO: 22), BATR $\alpha$ D (SEQ ID NO: 23) and BATR $\alpha$ E (SEQ ID NO: 24).
4. The method according to claim 1 or claim 2, wherein the humanized antibody comprises variable regions selected from the group consisting of: BATR $\alpha$ /BATR $\kappa$ A (SEQ ID NO: 20/SEQ ID NO: 15), BATR $\alpha$ B/BATR $\kappa$ A (SEQ ID NO: 21/SEQ ID NO: 15),

BATRHB/BATR $\kappa$ B (SEQ ID NO: 21/SEQ ID NO: 16), BATRHC/BATR $\kappa$ B (SEQ ID NO: 22/SEQ ID NO: 16), BATRHB/BATR $\kappa$ D (SEQ ID NO: 21/SEQ ID NO: 18), and BATRHC/BATR $\kappa$ D (SEQ ID NO: 22/SEQ ID NO: 18).

5. The method according to claim 4, wherein the humanized monoclonal antibody has variable regions corresponding to BATRHC/BATR $\kappa$ D (SEQ ID NO: 22/SEQ ID NO: 18).
6. The method according to claim 1 or claim 2, wherein the fragment of the humanized antibody is selected from the group consisting of: Fv, Fab', F(ab')2, and a single chain antibody.
7. The method according to claim 1 or claim 2, wherein the humanized antibody or the fragment thereof retains the antitumor activity of mBAT-1.
8. The method according to claim 1 or claim 2, wherein the at least one chemotherapeutic agent is selected from the group consisting of: antimetabolites, platinum-based agents, mitotic inhibitors, anthracycline antibiotics, topoisomerase inhibitors, anti-angiogenic agents and combinations thereof.
9. The method according to claim 1 or claim 2, wherein the at least one chemotherapeutic agent is other than an agent selected from the group consisting of: a topoisomerase I inhibitor and an alkylating agent.
10. The method according to claim 9, wherein the at least one chemotherapeutic agent is selected from the group consisting of: an antimetabolite selected from the group consisting of: 5-fluorouracil, uracil mustard, uracil, capecitabine, 6-mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine, and pemetrexed; a platinum-based agent selected from the group consisting of: cisplatin, carboplatin and oxaliplatin; a mitotic inhibitor selected from the group consisting of: paclitaxel, docetaxel, etoposide, vinblastine, vincristine and vinorelbine; an anti-angiogenic agent selected from the group consisting of: bevacizumab, dopamine, tetrathiomolybdate, anti-angiogenic variants of VEGF; and combinations thereof
11. The method according to claim 9, wherein the at least one chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof.

12. The method according to claim 1 or claim 2, wherein the administering of the humanized antibody is carried out prior to initial administration of the at least one chemotherapeutic agent.
13. The method according to claim 1 or claim 2 wherein the administering of either or both of the humanized antibody and the at least one chemotherapeutic agent is carried out by a route selected from the group consisting of intravenous, oral, intraperitoneal, subcutaneous, isolated limb perfusion, infusion into an organ and combinations thereof.
14. The method according to claim 1 or claim 2, further comprising treating the subject with radiation; or further comprising assessing at least one parameter selected from the group consisting of: rate of tumor growth, tumor volume, number of metastases, tumor recurrence and combinations thereof.
15. The method according to claim 1, wherein the tumor is selected from the group consisting of colorectal carcinoma; lung carcinoma; breast carcinoma; melanoma; ovarian carcinoma; cervical carcinoma, pancreatic cancer; multiple myeloma; renal cell carcinoma; non-Hodgkin's lymphoma; Hodgkin's disease; mantle cell lymphoma; Kaposi's sarcoma; squamous cell carcinoma; basal cell carcinoma; acute myeloid leukemia (AML); chronic myelocytic leukemia (CML); acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
16. The method according to claim 1 or claim 2 wherein the light chain variable region of the humanized monoclonal antibody is SEQ ID NO. 18, the heavy chain variable region of the humanized monoclonal antibody is SEQ ID NO. 22, the chemotherapeutic agent is an antimetabolite such as 5-fluorouracil and the tumor is melanoma.
17. A method of treating a tumor or enhancing survival of a subject having a tumor, the method comprising (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a functional fragment thereof, wherein the antibody or the fragment thereof has at least one complementarity determining region of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent wherein administering said humanized antibody and said at least one chemotherapeutic agent is carried out substantially simultaneously, concurrently, alternately, sequentially, successively or

according to an overlapping schedule; thereby treating the tumor or enhancing survival of the subject having the tumor, said method being further characterized in that on administering there is established a synergistic relationship between said components (i) and (ii).

18. The method according to claim 17, wherein the humanized antibody comprises: a light chain variable region selected from the group consisting of: BATR $\kappa$ A (SEQ ID NO: 15), BATR $\kappa$ B (SEQ ID NO: 16), BATR $\kappa$ C (SEQ ID NO: 17), and BATR $\kappa$ D (SEQ ID NO: 18), and a heavy chain variable region selected from the group consisting of: BATR $\alpha$ A (SEQ ID NO: 20), BATR $\alpha$ B (SEQ ID NO: 21), BATR $\alpha$ C (SEQ ID NO: 22), BATR $\alpha$ D (SEQ ID NO: 23) and BATR $\alpha$ E (SEQ ID NO: 24).
19. The method according to claim 18, wherein the humanized monoclonal antibody has variable regions corresponding to BATR $\alpha$ C/BATR $\kappa$ D (SEQ ID NO: 22/SEQ ID NO: 18).
20. The method according to claim 17, wherein the at least one chemotherapeutic agent is selected from the group consisting of: antimetabolites, platinum-based agents, mitotic inhibitors, anthracycline antibiotics, topoisomerase inhibitors, anti-angiogenic agents and combinations thereof.

1/20

FIGURE 1A




FIGURE 1B




FIGURE 1C




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A





FIGURE 4B






FIGURE 5A




FIGURE 5B

FIGURE 6A




FIGURE 6B




FIGURE 6C




FIGURE 7A





FIGURE 7B






FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15

FIGURE 16A




FIGURE 16B




FIGURE 17A





FIGURE 17B



18/20




FIGURE 18

19/20

## FIGURE 19

20/20

## FIGURE 20

CT 008 PCT SEQUENCE LISTING.txt  
SEQUENCE LISTING

<110> CureTech, Ltd.

<120> MONOCLONAL ANTIBODIES FOR TUMOR TREATMENT

<130> CT/008 PCT

<140> US 61/027,501

<141> 2008-02-11

<140> US 61/037,340

<141> 2008-03-18

<140> US 61/116,319

<141> 2008-11-20

<160> 193

<170> PatentIn version 3.3

<210> 1

<211> 23

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide

<400> 1

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys  
20

<210> 2

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = Phe or Tyr

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> Xaa = Trp or Leu

<400> 2

Trp Xaa Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Xaa Ile Tyr  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

<210> 3  
<211> 32  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (14)..(14)  
<223> Xaa = Asp or Ser

<220>  
<221> MISC\_FEATURE  
<222> (15)..(15)  
<223> Xaa = Tyr or Phe

<220>  
<221> MISC\_FEATURE  
<222> (16)..(16)  
<223> Xaa = Cys or Thr

<400> 3

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Thr Xaa Xaa Xaa  
1 5 10 15

Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys  
20 25 30

<210> 4  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 4

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
1 5 10

<210> 5  
<211> 30  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = Ile or Val

## CT 008 PCT SEQUENCE LISTING.txt

<220>  
<221> MISC\_FEATURE  
<222> (28)..(28)  
<223> Xaa = Thr or ser

<220>  
<221> MISC\_FEATURE  
<222> (30)..(30)  
<223> Xaa = Thr or Ser

<400> 5

Gln Xaa Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Xaa Phe Xaa  
20 25 30

<210> 6  
<211> 14  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Arg or Lys

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> Xaa = Gln or Lys

<400> 6

Trp Val Xaa Gln Ala Pro Gly Gln Gly Leu Xaa Trp Met Gly  
1 5 10

<210> 7  
<211> 32  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Val or Ala

<220>  
<221> MISC\_FEATURE

## CT 008 PCT SEQUENCE LISTING.txt

<222> (11)..(11)  
<223> Xaa = Asn or Ser

<220>  
<221> MISC\_FEATURE  
<222> (21)..(21)  
<223> Xaa = Thr or Asn

<220>  
<221> MISC\_FEATURE  
<222> (31)..(31)  
<223> Xaa = Val or Ala

<220>  
<221> MISC\_FEATURE  
<222> (32)..(32)  
<223> Xaa = Arg or Lys

<400> 7

Arg Phe Xaa Phe Ser Leu Asp Thr Ser Val Xaa Thr Ala Tyr Leu Gln  
1 5 10 15

Ile Thr Ser Leu Xaa Ala Glu Asp Thr Gly Met Tyr Phe Cys Xaa Xaa  
20 25 30

<210> 8  
<211> 11  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 8

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
1 5 10

<210> 9  
<211> 10  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 9

Ser Ala Arg Ser Ser Val Ser Tyr Met His  
1 5 10

<210> 10  
<211> 7  
<212> PRT  
<213> Artificial sequence

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 10

Arg Thr Ser Asn Leu Ala Ser  
1 5

&lt;210&gt; 11

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 11

Gln Gln Arg Ser Ser Phe Pro Leu Thr  
1 5

&lt;210&gt; 12

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 12

Asn Tyr Gly Met Asn  
1 5

&lt;210&gt; 13

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 13

Trp Ile Asn Thr Asp Ser Gly Ser Thr Tyr Ala Glu Glu Phe Lys  
1 5 10 15

Gly

&lt;210&gt; 14

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

## CT 008 PCT SEQUENCE LISTING.txt

<223> Synthetic peptide

<400> 14

Val Gly Tyr Asp Ala Leu Asp Tyr  
1 5

<210> 15

<211> 106

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide

<400> 15

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr  
35 40 45

Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu  
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro Leu Thr  
85 90 95

Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 16

<211> 106

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide

<400> 16

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
Page 6

## CT 008 PCT SEQUENCE LISTING.txt

20 25 30

His Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp Ile Tyr  
35 40 45

Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu  
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro Leu Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 17

<211> 106

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide

<400> 17

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp Ile Tyr  
35 40 45

Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Asp Tyr Cys Leu Thr Ile Asn Ser Leu Gln Pro Glu  
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro Leu Thr  
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

## CT 008 PCT SEQUENCE LISTING.txt

<210> 18  
<211> 106  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 18

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Trp Ile Tyr  
35 40 45

Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Cys Leu Thr Ile Asn Ser Leu Gln Pro Glu  
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro Leu Thr  
85 90 95

Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 19  
<211> 128  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 19

Met Asp Leu Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser  
1 5 10 15

Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile  
20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Ser Ala Arg  
35 40 45

Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr Ser  
Page 8

## CT 008 PCT SEQUENCE LISTING.txt

50 55 60

Pro Lys Leu Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro  
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Thr Ser Tyr Cys Leu Thr Ile  
85 90 95

Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg  
100 105 110

Ser Ser Phe Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
115 120 125

<210> 20  
<211> 117  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 20

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asn Tyr  
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Ala Lys Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

## CT 008 PCT SEQUENCE LISTING.txt

<210> 21  
<211> 117  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 21

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Ala Lys Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 22  
<211> 117  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 22

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

## CT 008 PCT SEQUENCE LISTING.txt

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Val Arg Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 23  
<211> 117  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 23

Gln Ile Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Val Arg Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

## CT 008 PCT SEQUENCE LISTING.txt

Val Thr Val Ser Ser  
115

<210> 24  
<211> 117  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 24

Gln Ile Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Asp Thr Ser Val Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Asn Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Val Arg Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 25  
<211> 384  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 25  
atggatttac aggtgcagat tatcagcttc ctgctaatca gtgcctcagt cataatgtcc 60

agaggacaaa ttgttctcac ccagtctcca gcaatcatgt ctgcacttcc aggggagaag 120

gtcaccataa cctgcagtgc caggtcaagt gtaagttaca tgcactgggtt ccagcagaag 180

## CT 008 PCT SEQUENCE LISTING.txt

ccaggcactt ctcccaaact ctggatttat aggacatcca acctggcttc tggagtccct 240  
gctcgcttca gtggcagtgg atctgggacc tcctactgtc tcacaatcag ccgaatggag 300  
gctgaagatg ctgccactta ttactgccag caaaggagta gttcccaact cacgttcggc 360  
tcggggacaaa agttggaaat aaaa 384

<210> 26  
<211> 136  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthetic peptide

<400> 26

Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser  
1 5 10 15

Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys  
20 25 30

Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
35 40 45

Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu  
50 55 60

Lys Trp Met Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala  
65 70 75 80

Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn  
85 90 95

Thr Ala Tyr Leu Gln Ile Asn Asn Leu Asn Asn Glu Asp Thr Ala Thr  
100 105 110

Tyr Phe Cys Val Arg Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln  
115 120 125

Gly Thr Ser Val Thr Val Ser Ser  
130 135

<210> 27  
<211> 408  
<212> DNA  
<213> Artificial sequence

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 27

atggctggg tgtggacctt gctattctg atggcagctg cccaaagtat ccaagcacag 60  
atccagttgg tgcagtctgg acctgagttg aagaaggctg gagagacagt caagatctcc 120  
tgcaaggctt ctggatatac tttcacaaac tatggaatga actgggtgaa gcaggctcca 180  
ggaaagggtt taaagtggat gggctggata aacaccgaca gtggagagtc aacatatgct 240  
gaagagttca agggacggtt tgccctctct ttggaaacct ctgccaacac tgcctattg 300  
cagatcaaca acctaaca tgaggacacg gctacatatt tctgtgtgag agtcggctac 360  
gatgcattgg actactgggg tcaaggaacc tcagtcaccg tctcctca 408

&lt;210&gt; 28

&lt;211&gt; 107

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 28

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr  
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Ser Phe Pro Leu  
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

&lt;210&gt; 29

&lt;211&gt; 120

&lt;212&gt; PRT

&lt;213&gt; Artificial sequence

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 29

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Ser His  
20 25 30

Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Ser Pro Thr Tyr Ala Gln Gly Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Ala Lys Glu Ser His Ser Ser Ala Leu Asp Leu Asp Tyr Trp Gly Gln  
100 105 110

Gly Thr Leu Val Thr Val Ser Ser  
115 120

&lt;210&gt; 30

&lt;211&gt; 43

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 30

cccaagcttg ccggccacccat ggacatgagg gtcccccgtc agc 43

&lt;210&gt; 31

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 31

tcctggggct cctgctgctc tggctcccaag gtgcattatg 40

## CT 008 PCT SEQUENCE LISTING.txt

<210> 32  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 32  
tgaaattgtg ttgacgcagt ctccatccctc cctgtctgca 40

<210> 33  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 33  
tctgttagag acagagtcac catcaattgc agtgcagg 40

<210> 34  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 34  
caagttaag ttacatgcac tggatcagc agaaaccagg 40

<210> 35  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 35  
gaaaggccct aagctcctga tctataggac atccaacctg 40

<210> 36  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 36  
gcttctgggg tcccatctag attcagcggc agtggatctg 40

## CT 008 PCT SEQUENCE LISTING.txt

<210> 37  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 37  
ggacagattt cacttcacc atcaacagcc tgcagcctga 40

<210> 38  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 38  
agatttgca acttactatt gccagcaaag gagtagttc 40

<210> 39  
<211> 55  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 39  
ccactcacgt tcggcggagg gaccaagctg gagatcaaac gtgagtggat ccgcg 55

<210> 40  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 40  
gaggcaggcagg agccccagga gctgagcggg gaccctcatg 40

<210> 41  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 41  
actgcgtcaa cacaattca catttggcac ctgggagcca 40

<210> 42

## CT 008 PCT SEQUENCE LISTING.txt

<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 42  
gtgactctgt ctcctacaga tgcagacagg gaggatggag

40

<210> 43  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 43  
gtgcatgtaa cttacacttg acctggcact gcaagtgtg

40

<210> 44  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 44  
tcaggagctt aggggcttc cctggttct gctgataccca

40

<210> 45  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 45  
ctagatggaa ccccagaagg cagggtggat gtcctataga

40

<210> 46  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 46  
ggtgagatgtt aatctgtcc cagatccact gccgctgaat

40

<210> 47  
<211> 40

## CT 008 PCT SEQUENCE LISTING.txt

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 47

aatagtaagt tgcaaaatct tcaggctgca ggctgttgat 40

&lt;210&gt; 48

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 48

cctccgcccga acgtgagtgaaactactc ctggctggc 40

&lt;210&gt; 49

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 49

cgcgatcca ctcacgttg atctccagct tggc 35

&lt;210&gt; 50

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 50

caagttaag ttacatgcac tggccagc agaaaccagg 40

&lt;210&gt; 51

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 51

gaaagccctt aagctctgga tctataggac atccaacctg 40

&lt;210&gt; 52

&lt;211&gt; 40

&lt;212&gt; DNA

## CT 008 PCT SEQUENCE LISTING.txt

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 52

ggacagattt cacttcacc atcaacagcc tgcagcctga 40

<210> 53

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 53

tccagagctt aggggcttc cctggttct gctgaaacca 40

<210> 54

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 54

ggtgagagtg taatctgtcc cagatccact gccgctgaac 40

<210> 55

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 55

ggtgagacag taagatgtcc cagatccact gccgctgaac 40

<210> 56

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 56

ggacatctta ctgttcacc atcaacagcc tgcagcctga 40

<210> 57

<211> 40

<212> DNA

<213> Artificial sequence

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 57

cccaagcttg ccgccaccat ggactggacc tggaggatcc 40

&lt;210&gt; 58

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 58

tcttcgtt ggcagcagca acaggtgccc act 33

&lt;210&gt; 59

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 59

cccgaggc gctggcaca tctgggtctg agcttaagaa 40

&lt;210&gt; 60

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 60

gcctggggcc tcagtgaaga tctcgtcaca ggcttctgga 40

&lt;210&gt; 61

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 61

tatagttca gtaactatgg aatgaactgg gtgcgacagg 40

&lt;210&gt; 62

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 62

ccccctggaca agggcttcag tggatggat ggataaacac 40

&lt;210&gt; 63

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 63

cgacagtggaa gagtcaacat atgctgaaga gttcaaggga 40

&lt;210&gt; 64

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 64

cggttgtct tctccttggaa cacctctgtc agcacggcat 40

&lt;210&gt; 65

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 65

atctgcagat caccagcctc acggctgagg acactggcat 40

&lt;210&gt; 66

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Synthetic polynucleotide

&lt;400&gt; 66

gtatttctgt gcgaaagtgc gctacgatgc ttgg 35

&lt;210&gt; 67

&lt;211&gt; 54

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

## CT 008 PCT SEQUENCE LISTING.txt

<223> Synthetic polynucleotide

<400> 67

actactgggg ccagggAACc ctggtcaccc tctcctcagg tgagtggatc cgcg 54

<210> 68

<211> 45

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 68

tgctgccacc aagaagagga tccttccagg tggagtccat ggtgg 45

<210> 69

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 69

ttgcaccaggc tgcacctggg agtgggcacc tggc 36

<210> 70

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 70

tcttcactga ggcccccaggc ttcttaagct cagacccaga 40

<210> 71

<211> 39

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 71

ccatagttac tgaagctata tccagaagct tgcaggaga 39

<210> 72

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic polynucleotide

## CT 008 PCT SEQUENCE LISTING.txt

<400> 72  
ctgaaggccct tgtccagggg cctgtcgac ccagttcatt 40

<210> 73  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 73  
atgtgactc tccactgtcg gtgttatcc atcccatcca 40

<210> 74  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 74  
tccaaggaga agacaaaccg tcccttgaac tcttcagcat 40

<210> 75  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 75  
gaggctggtg atctgcagat atgccgtgct gacagagggt 40

<210> 76  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 76  
cgactttcgc acagaaatac atgccagtgt cctcagccgt 40

<210> 77  
<211> 33  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

## CT 008 PCT SEQUENCE LISTING.txt

<400> 77  
ttccctggcc ccagtagtcc aaagcatcgt agc 33

<210> 78  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 78  
cgcgatcca ctcacctgag gagacggta ccaggg 36

<210> 79  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 79  
tatacttca caaactatgg aatgaactgg gtgcgacagg 40

<210> 80  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 80  
ccatagttg tgaaagtata tccagaagcc ttgcaggaga 40

<210> 81  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 81  
cggttgtct tctccttggaa cacctctgtc aacacggcat 40

<210> 82  
<211> 35  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 82

## CT 008 PCT SEQUENCE LISTING.txt

gtatttctgt gtgagagtgc gctacgatgc ttgg 35

<210> 83  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 83  
cgactctcac acagaataac atgccagtgt cctcagccgt 40

<210> 84  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 84  
atctgcagat caccagcctc aacgctgagg acactggcat 40

<210> 85  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 85  
gaggctggtg atctgcagat atgccgtgtt gacagagggt 40

<210> 86  
<211> 40  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 86  
tatacttca caaactatgg aatgaactgg gtgaaggcagg 40

<210> 87  
<211> 412  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 87  
aagcttgccg ccaccatgga catgagggtc cccgctcagc tcctggggct cctgctgctc 60

## CT 008 PCT SEQUENCE LISTING.txt

tggctccag gtgccaaatg taaaattgtt ttgacgcagt ctccatcctc cctgtctgca 120  
tctgttaggag acagagtcac catcaactgc agtgcgcaggtaa gaaatgtt 180  
tggatcaggc agaaaccagg gaaagccct aagctctga tctataggac atccaacctg 240  
gcttcgggg tcccatctag attcagccgc agtggatctg ggacagattt cactctcacc 300  
atcaacagcc tgcagccctga agattttgca acttactatt gccagcaaag gagtagttc 360  
ccactcacgt tcggcgagg gaccaagctg gagatcaaac gtgagtggat cc 412

<210> 88  
<211> 412  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 88  
aagctgcgg ccaccatgga catgagggtc cccgctcagc tcctggggct cctgctgctc 60  
tggctccag gtgccaaatg taaaattgtt ttgacgcagt ctccatcctc cctgtctgca 120  
tctgttaggag acagagtcac catcaactgc agtgcgcaggtaa gaaatgtt 180  
tggatcaggc agaaaccagg gaaagccct aagctctga tctataggac atccaacctg 240  
gcttcgggg tcccatctag attcagccgc agtggatctg ggacagattt cactctcacc 300  
atcaacagcc tgcagccctga agattttgca acttactatt gccagcaaag gagtagttc 360  
ccactcacgt tcggcgagg gaccaagctg gagatcaaac gtgagtggat cc 412

<210> 89  
<211> 412  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 89  
aagctgcgg ccaccatgga catgagggtc cccgctcagc tcctggggct cctgctgctc 60  
tggctccag gtgccaaatg taaaattgtt ttgacgcagt ctccatcctc cctgtctgca 120  
tctgttaggag acagagtcac catcaactgc agtgcgcaggtaa gaaatgtt 180  
tggatcaggc agaaaccagg gaaagccct aagctctga tctataggac atccaacctg 240  
gcttcgggg tcccatctag attcagccgc agtggatctg ggacatctt ctttccacc 300  
atcaacagcc tgcagccctga agattttgca acttactatt gccagcaaag gagtagttc 360  
ccactcacgt tcggcgagg gaccaagctg gagatcaaac gtgagtggat cc 412

## CT 008 PCT SEQUENCE LISTING.txt

<210> 90  
<211> 436  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 90  
aagctgccg ccaccatgga ctggacctgg aggatccctct tctggtggc agcagcaaca 60  
ggtccccact cccaggtgca gctggtgcaa tctgggtctg agcttaagaa gcctggggcc 120  
tcagtgaaga ttcctgcaa ggcttctgga tatacttca caaactatgg aatgaactgg 180  
gtgcgacagg cccctggaca agggcttcag tggatggat ggataaacac cgacagtgg 240  
gagtcaacat atgctgaaga gttcaaggga cggttgtct ttccttgga cacctctgtc 300  
aacacggcat atctcgat caccgcctc acggctgagg acactggcat gtattctgt 360  
gtgagagtgc gctacgatgc ttggactac tggggccagg gaaccctggt caccgtctcc 420  
tcaggtgagt ggatcc 436

<210> 91  
<211> 436  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

<400> 91  
aagctgccg ccaccatgga ctggacctgg aggatccctct tctggtggc agcagcaaca 60  
ggtccccact cccaggtgca gctggtgcaa tctgggtctg agcttaagaa gcctggggcc 120  
tcagtgaaga ttcctgcaa ggcttctgga tatacttca caaactatgg aatgaactgg 180  
gtgcgacagg cccctggaca agggcttcag tggatggat ggataaacac cgacagtgg 240  
gagtcaacat atgctgaaga gttcaaggga cggttgtct ttccttgga cacctctgtc 300  
agcacggcat atctcgat caccgcctc acggctgagg acactggcat gtattctgt 360  
gcgaaagtgc gctacgatgc ttggactac tggggccagg gaaccctggt caccgtctcc 420  
tcaggtgagt ggatcc 436

<210> 92  
<211> 436  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthetic polynucleotide

## CT 008 PCT SEQUENCE LISTING.txt

<400> 92  
 aagctgccc ccaccatgga ctggacctgg aggatcctct tctgggtggc agcagcaaca 60  
 ggtgcccaact cccaggtgca gctggtgcaa tctgggtctg agcttaagaa gcctggggcc 120  
 tcagtgaaga tctcctgcaa ggctctgga tatacttca caaactatgg aatgaactgg 180  
 gtgcgacagg cccctggaca agggcctcag tggatggat ggataaacac cgacagtgg 240  
 gagtcaacat atgctgaaga gttcaaggga cggttgtct tctcctgga cacctctgtc 300  
 agcacggcat atctgcagat caccagcctc acggctgagg acactggcat gtatttctgt 360  
 gcgaaagtgc gctacgatgc ttggactac tggggccagg gaaccctggt caccgtctcc 420  
 tcaggtgagt ggatcc 436

<210> 93  
 <211> 10259  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> pG1KD210.BAT-1.RHC/RkD single expression vector  
 <400> 93  
 ttgaagacga aagggccctcg tgatacgcct attttatag gtaatgtca tgataataat 60  
 ggttcttag acgtcaggtg gcactttcg gggaaatgtg cgcggAACCC ctattgttt 120  
 attttctaa atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgtc 180  
 tcaataataat taaaaaggaa agagtatgag tattcaacat ttccgtgtcg cccttattcc 240  
 ctttttgcg gcattttgcc ttccgttt tgctcaccca gaaacgctgg tgaaagtaaa 300  
 agatgctgaa gatcagttgg gtgcacgagt gggttacatc gaactggatc tcaacagcgg 360  
 taagatcctt gagagtttc gccccgaaga acgtttcca atgatgagca ctttaaagt 420  
 tctgctatgt ggcgcggat tatcccggt tgacgcggg caagagcaac tcggcgccg 480  
 catacactat ttcagaatg actgggtga gtactcacca gtcacagaaa agcatctac 540  
 ggtatggcatg acagtaagag aattatgcag tgctccata accatgagtg ataacactgc 600  
 ggccaaactta ctctgaccaa cgatcggagg accgaaggag ctaaccgctt tttgcacaa 660  
 catgggggat catgtaaactc gccttgcgtc ttggaaaccg gagctgaatg aagccataacc 720  
 aaacgacgag cgtgacacca cgatgcctgc agcaatggca acaacgttc gcaaactatt 780  
 aactggcgaa ctacttactc tagctcccg gcaacaatta atagactggta tggaggcgga 840  
 taaagtgcgaa ggaccacttc tgcgctcgcc ccttccggct ggctgggtta ttgctgataa 900  
 atctggagcc ggtgagcgtg ggtctcgccg tatcattgca gcactggggc cagatggtaa 960  
 gcccctccgt atcgttagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa 1020

## CT 008 PCT SEQUENCE LISTING.txt

tagacagatc gctgagatag gtgcctcaact gattaagcat tggtaactgt cagaccaagt 1080  
ttactcatat atactttaga ttgatttaaa acttcattt taatttaaaa ggatcttagt 1140  
gaagatcctt ttgataatc tcatgaccaa aatccctaa cgtgagttt cgtccactg 1200  
agcgtcagac cccgtagaaa agatcaaagg atctcttga gatccctttt ttctgcgcgt 1260  
aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg gtggttgtt tgccggatca 1320  
agagctacca actcttttc cgaaggtaac tggctcagc agagcgcaga taccaaatac 1380  
tgcccttcta gtgtagccgt agttaggcca ccactcaag aactctgtag caccgcctac 1440  
atacctcgct ctgctaattcc tggtaaccgt ggctgctgcc agtggcgata agtcgtgtct 1500  
tacccgggtt gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg 1560  
gggttcgtgc acacagccca gctggagcg aacgacctac accgaactga gataacctaca 1620  
gcgtgagcta tgagaaagcg ccacgctcc cgaagggaga aaggcggaca ggtatccggt 1680  
aagcggcagg gtcggaacag gagagcgcac gagggagctt ccagggggaa acgcctggta 1740  
tctttatagt cctgtcgggt ttcgccacct ctgacttgag cgtcgattt tggatgctc 1800  
gtcaggggggg cgagacccat gaaaaaacgc cagcaacgcg gcctttac ggttcctggc 1860  
ctttgctgg cctttgctc acatgttctt tccctgcgtt tccctgatt ctgtggataa 1920  
ccgttaattacc gcctttgagt gagctgatac cgctcgcgc agccgaacga ccgagcgcag 1980  
cgagtcagtg agcgaggaag cggaagagcg cctgatgcgg tattttctcc ttacgcatct 2040  
gtgcgttattt tcacaccgca tatggtgcac tctcagtaca atctgctctg atgcccata 2100  
gttaagccag tataactcc gctatcgcta cgtgactggg tcatggctgc gccccacac 2160  
ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc tcccgcatc cgcttacaga 2220  
caagctgtga ccgtctccgg gagctgcgtg tgcagaggt ttcaccgtc atcaccgaaa 2280  
cgcgcgaggc agcatgcac tcaattagtc agcaaccata gtcccgcccc taactccgcc 2340  
catcccgcccc ctaactccgc ccagttccgc ccattctccg ccccatggct gactaattt 2400  
ttttatgttgcagaggccg aggccgcctc ggcctctgag ctattccaga agtagtgagg 2460  
aggctttttt ggaggccctag gctttgcata aaagcttagt tacagctcgt ggctgcgtt 2520  
tcgcgcacaaa ctgcacggca atcctagcgt gaaggctggt aggatttat ccccgctgcc 2580  
atcatggttc gaccattgaa ctgcacgc tccgcgtccc aaaatatggg gatggcaag 2640  
aacggagacc taccctggcc tccgcgtcagg aacgagttca agtacttcca aagaatgacc 2700  
acaaccttcc cagtggagg taaacagaat ctgggttgcata tgggttagaa aacctgggtc 2760  
tccattcctg agaagaatcg acctttaaaag gacagaatta atatagttct cagttagagaa 2820  
ctcaaagaac caccacgagg agctcattt ctgcacaaa gttggatga tgccttaaga 2880

## CT 008 PCT SEQUENCE LISTING.txt

cttattgaac aaccggaatt ggcaagtaaa gtagacatgg ttggatagt cgaggcagt 2940  
tctgttacc aggaagccat gaatcaacca gcccaccta gactttgt gacaaggatc 3000  
atgcaggaat ttgaaagtga cacgtttc ccagaaattg atttgggaa atataaactt 3060  
ctcccagaat acccaggcgt cctctctgag gtccaggagg aaaaaggcat caagtataag 3120  
tttgaagtct acgagaagaa agactaacag gaagatgctt tcaagtctc tgctccctc 3180  
ctaaagctat gcattttat aagaccatgg gactttgct ggcttagat ctttgtaag 3240  
gaaccttact tctgtgggt gacataattg gacaaactac ctacagagat taaagctct 3300  
aaggtaataa taaaatttt aagtgtataa tggtaaac tactgattct aattgttgt 3360  
gtattttaga ttccaaccta tggaactgat gaatgggagc agtggtgaa tgcccttaat 3420  
gaggaaaacc tgtttgctc agaagaaaatg ccatctagt atgatgaggc tactgctgac 3480  
tctcaacatt ctactcctcc aaaaaagaag agaaaggtag aagacccaa ggactttct 3540  
tcagaattgc taagttttt gagtcatgct gtgttagta atagaactct tgctgctt 3600  
gctatttaca ccacaaagga aaaagctgca ctgctataca agaaaattat ggaaaaatat 3660  
tctgttaacct ttataaggtag gcataacagt tataatcata acatactgtt tttcttact 3720  
ccacacaggc atagagtgtc tgctttaat aactatgctc aaaaattgtg taccttagc 3780  
tttttaattt gtaaagggtt taataaggaa tatttgatgt atagtgcctt gactagagat 3840  
cataatcagc cataccacat tttagaggt ttacttgct taaaaaaacc tcccacacct 3900  
ccccctgaac ctgaaacata aatgaatgc aattgtgtt gttaactgtt ttattgcagc 3960  
ttataatggt tacaataaaa gcaatagcat cacaatttc acaaataaaag catttttc 4020  
actgcattct agttgtgggt tgccttact catcaatgta tcttacatg tctactagt 4080  
gccggccccc gcgatcgctc gagatatcta ttaatagtaa tcaattacgg ggtcattagt 4140  
tcatagccca tataatggagt tccgcgttac ataactacg gttaatggcc cgcctggctg 4200  
accgcacac gaccccgcc cattgacgtc aataatgacg tatgtccca tagtaacgcc 4260  
aatagggact ttccattgac gtcaatgggt ggagtattta cggtaaactg cccactggc 4320  
agtacatcaa gtgtatcata tgccaagtac gccccctatt gacgtcaatg acggtaaatg 4380  
gccccctgg cattatgccc agtacatgac ctatggac ttccctactt ggcagtacat 4440  
ctacgttata gtcacatgta ttaccatgtt gatgcggttt tggcagtaca tcaatggcg 4500  
tggatagcgg ttgactcac ggggattcc aagtctccac cccattgacg tcaatggag 4560  
ttgttttgg caccaaaatc aacgggactt tccaaaatgt cgtaacaact cggccccatt 4620  
gacgcaaatg ggcggtaggc gtgtacgggt ggaggctat ataagcagag ctcgttagt 4680

## CT 008 PCT SEQUENCE LISTING.txt

gaaccgtca gatcgccatcc acgctgttt gacccatcc gaaagacaccg 4740  
ggaccgatcc agcctccgcg gcccggaaacg gtgcatttga acgcggattc cccgtgcca 4800  
gagtgacgta agtaccgcct atagagtcta taggcccacc cccctggctt ctatgcatt 4860  
ctatactgtt ttggcttgg ggtctataca ccccccgttc ctcatgtt atggatgg 4920  
atagcttagc ctatagggtt gggttattga ccattattga ccactccctt attggtgacg 4980  
atacttcca ttactaatcc ataacatggc tcttgccac aactctttt attggctata 5040  
tgccaataca ctgtccttca gagactgaca cggactctgt attttacag gatggggct 5100  
catttattat ttacaaattc acatatacaa caccaccgtc cccagtgcgc gcagtttta 5160  
ttaaacataa cgtggatct ccacgcgaat ctgggtacg tggccggac atgggcttt 5220  
ctccggtagc ggcggagctt ctacatccga gccctgtcc catgcctcca gcgactcatg 5280  
gtcgctcggc agtccttgc tcctaacagt ggaggccaga cttaggcaca gcacgtgcc 5340  
caccaccacc agtgtgccgc acaaggccgt ggcggtaggg tatgtgtctg aaaatgagct 5400  
cggggagcgg gcttgcaccg ctgacgcatt tggaaagactt aaggcagcgg cagaagaaga 5460  
tgcaggcagc tgagtgttg tggctgtata agagtcagag gtaactcccg ttgcgggtct 5520  
gttaacggtg gagggcagtg tagtctgagc agtactcggt gctgcccgcg gcccaccag 5580  
acataatagc tgacagacta acagactgtt ccttccatg ggtctttct gcagtccaccg 5640  
tccttgacac gcgtctcggg aagcttgccg ccaccatggc catgagggtc cccgctcagc 5700  
tcctggggct cctgctgctc tggctccag gtgccaaatg tgaaattgtg ttgacgcagt 5760  
ctccatcctc cctgtctgca tctgttaggag acagagtcac catcaactgc agtgccaggt 5820  
caagtgttaa ttacatgcac tggccacgc agaaaccagg gaaagccctt aagctctgg 5880  
tctataggac atccaacctg gcttctgggg tcccatctag attcagcggc agtggatctg 5940  
ggacatctta ctgtctcacc atcaacagcc tgcagccctga agatttgca acttactatt 6000  
gccagcaaag gagtagttc ccactcacgt tcggccggagg gaccaagctg gagatcaaac 6060  
gtgagtgatccatctggta taagcatgct gtttctgtc tggccctaaatg atggccctgt 6120  
attatgcgcac aacaacacac ccaagggcag aactttgttta cttaaacacc atcctgttt 6180  
cttccttcctt caggaactgtt ggctgcacca tctgtcttca tcttccggcc atctgtatgag 6240  
cagttgaaat ctggaaactgc ctctgttgtt tgcctgtca ataacttcta tccctggagag 6300  
gccaaggatc agtggaaagggt ggataacgcctt ccaccaatcggtt gtaactccca ggagatgtc 6360  
acagagcagg acagcaagga cagcacccatc agcctcagca gcaccctgac gctgagcaaa 6420  
gcagactacg agaaacacaa agtctacgccc tgcaaggta cccatcagggtt cctgagatgtc 6480  
cccgccacaa agagcttcaa cagggagag tggtagaggg agaagtgccc ccacctgctc 6540

## CT 008 PCT SEQUENCE LISTING.txt

ctcagttcca gcctgacccc ctcccatcct ttggcctctg acccttttc cacagggac 6600  
ctacccctat tgccgtcctc cagctcatct ttcacccac ccccccctc ctccttgct 6660  
ttaattatgc taatgttggaa ggagaatgaa taaataaaagt gaatcttgc acctgtggta 6720  
gatctaataa aagataattta ttttcattag atatgtgtg tggtttttg tgcagtgc 6780  
ctctatctgg aggccaggta gggctggcct tgggggaggg ggaggccaga atgactccaa 6840  
gagctacagg aaggcaggta agagacccccttggacaaac agtggctgga ctctgcacca 6900  
taacacacaa tcaacaggggg agtgagctgg aaatttgcta gcgaattcta ttaatagtaa 6960  
tcaattacgg ggtcattagt tcatagccca tataatggagt tccgcgtac ataacttacg 7020  
gtaaatggcc cgccctggctg accgccccaaac gaccccccgc cattgacgac aataatgacg 7080  
tatgttccca tagtaacgcc aataggact ttccattgtac gtcaatgggt ggagtattta 7140  
cggtaaaactg cccacttggc agtacatcaa gtgtatcata tgccaaagtac gccccctatt 7200  
gacgtcaatg acggtaatg gcccgcctgg cattatgccc agtacatgac ctatggac 7260  
ttccctactt ggcagtacat ctacgttataa gtcatcgta ttaccatgggt gatgcggtt 7320  
tggcagtaca tcaatggcg tggatagcgg ttgactcac ggggatttcc aagtctccac 7380  
cccatgtacg tcaatggag ttgttttgg cacaaaatc aacgggactt tccaaaatgt 7440  
cgtaacaact ccgccccatt gacgcaaatg ggcggtaggc gtgtacggtg ggaggctat 7500  
ataaggcagag ctcgttagt gaaccgtcag atgcctgga gacgcccattcc acgctgttt 7560  
gacccatccata gaagacacccg ggaccgatcc agcctccgcg gcccggaaacg gtgcattgga 7620  
acgcggattc cccgtccaa gagtgacgta agtaccgcct atagagtcta taggcccacc 7680  
cccttggctt ctatgcattt ctatactgtt ttggcttgg ggtctataca ccccccgttc 7740  
ctcatgttat aggtgatgggt atagcttagc ctatagggtt gggttattga ccattattga 7800  
ccactccccctt attggtgacg atactttcca ttactaatcc ataacatggc tctttgccac 7860  
aactctctt attggctata tgccaaataca ctgtcctca gagactgaca cgactctgt 7920  
attttacag gatggggctt catttattttttaacaaatcc acatatacaa caccaccgtc 7980  
cccagtgccttgcacgatgtttaacaaatcc cgtggatcttccacgcgttacg 8040  
tgtccggac atggcttccctt ctccggtagc ggcggagctt ctacatccga gcccgttcc 8100  
catgcctcca gcgactcatg gtgcgtccgc agtccttcgc tcctaacagt ggaggccaga 8160  
cttaggcaca gcacgtgcc caccaccacc agtgcgtccgc acaaggccgtt ggcggtaggg 8220  
tatgtgtctg aaaatgagct cggggagcgg gcttgcaccg ctgacgcattt gggaaagactt 8280  
aaggcagcgg cagaagaaga tgcaggcagc tgagttgtt gttctgata agagtcaag 8340

## CT 008 PCT SEQUENCE LISTING.txt

gtaactcccg ttgcgggtct gtaacgggtg gaggggcagtg tagtctgagc agtactcggt 8400  
gctgccgcgc gcccaccagg acataatagc tgacagacta acagactgtt ccttccatg 8460  
ggtccttctc gcagtcaccg tccttgacac gcgtctcggg aagctgtccg ccaccatgg 8520  
ctggacctgg aggatccctc tcttggggc agcagcaaca ggtgcccact cccaggtgca 8580  
gctggtgcaa tctgggtctg agcttaagaa gcctggggcc tcagtgaaga tctcctgcaa 8640  
ggcttctgga tatacttca caaactatgg aatgaactgg gtgcgacagg cccctggaca 8700  
agggcttcag tggatggat ggataaacac cgacagtgg aagtcaacat atgctgaaga 8760  
gttcaaggga cggttgctc tctcctgga cacctctgtc aacacggcat atctgcagat 8820  
caccagcctc acggctgagg acactggcat gtattctgt gtgagagtgc gctacgtgc 8880  
tttggactac tggggccagg gaaccctggt caccgtctcg agcgccctca ccaagggccc 8940  
atcggcttc cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg 9000  
ctgcctggtc aaggactact tcccgaaacc ggtgacgggtg tcgtgaaact caggcgccct 9060  
gaccagcggc gtgcacaccc tcccggtctg cctacagtcc tcaggactct actccctcag 9120  
cagcgtggtg accgtccct ccagcagctt gggcacccag acctacatct gcaacgtgaa 9180  
tcacaagccc agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac 9240  
tcacacatgc ccaccgtgcc cagcacctga actcctgggg ggaccgtca gttcccttt 9300  
ccccccaaaa cccaaggaca ccctcatgtat ctcccgacc cctgagggtca catgcgtgg 9360  
ggtggacgtg agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgg 9420  
ggtgcatataat gccaagacaa agccgcggga ggagcagtac aacagcacgt accgggtgg 9480  
cagcgtccctc accgtccctgc accaggactg gctgaatggc aaggagtaca agtgcacgg 9540  
ctccaacaaa gcccctccag ccccatcgaa gaaaaccatc tccaaagcca aagggcagcc 9600  
ccgagaacca caggttaca ccctggggcc atcccgaggag gagatgacca agaaccagg 9660  
cagcctgacc tgcctggta aaggcttcta tcccgacgc acgtgggtgg agtgggagag 9720  
caatggcgag cccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc 9780  
cttccttc tacagcaagc tcaccgtggta caagagcagg tggcagcagg ggaacgttt 9840  
ctcatgctcc gtgtatgcatg aggctctgca caaccactac acgcagaaga gcctctccct 9900  
gtctccgggt aaatgaggtgc gacggccggc aagcccccgt ccccggtc tcgcgtgc 9960  
acgaggatgc ttggcacgtta cccctgtac atactcccg ggcgcggcactg atggaaataa 10020  
agcaccggat ctaataaaag atatttattt tcattagata tgtgtgtgg tttttgtgt 10080  
gcagtcctc tatctggagg ccaggttaggg ctggccctgg gggaggggggaa ggccagaatg 10140  
actccaagag ctacaggaag gcaggtcaga gacccactg gacaaacagt ggctggactc 10200

## CT 008 PCT SEQUENCE LISTING.txt

tgccaccataa cacacaatca acaggggagt gagctggaaa ttgctagcg aattaattc 10259

<210> 94  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 94

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr Arg  
35 40 45

Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Leu Thr Ile Ser Arg Met Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro  
85 90

<210> 95  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 95

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Val Ser Tyr Met  
20 25 30

His Tyr Gln Tyr Lys Pro Gly Thr Ser Ser Lys Leu Pro Ser Tyr Arg  
35 40 45

Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu Asp  
65 70 75 80

## CT 008 PCT SEQUENCE LISTING.txt

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr His Phe Tyr  
85 90

<210> 96  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 96

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Gln Tyr Lys Pro Gly Ser Ser Pro Lys Leu Arg Ile Tyr Arg  
35 40 45

Asp Ser Asn Lys Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Trp Ser Phe Asn  
85 90

<210> 97  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 97

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ile Tyr Met  
20 25 30

His Trp Gln Tyr Lys Pro Gly Thr Ser Pro Lys Leu Arg Ile Tyr Arg  
35 40 45

Asp Ser Asn Lys Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu Asp  
Page 36

## CT 008 PCT SEQUENCE LISTING.txt

65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln His Arg Ser Ser Phe Tyr  
85 90

&lt;210&gt; 98

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 98

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Tyr Gln Tyr Lys Pro Gly Thr Arg Ser Lys Leu Pro Ile Tyr Arg  
35 40 45

Leu Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Trp Ser Phe Asn  
85 90

&lt;210&gt; 99

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (34)..(34)

&lt;223&gt; Xaa can be any naturally occurring amino acid

&lt;400&gt; 99

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Xaa Gln Gln Lys Pro Gly Thr Ser Ser Lys Leu Trp Ile Tyr Arg  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Ser Ile Asn Lys Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Val Lys Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Trp Ser Phe Ser  
85 90

<210> 100  
<211> 94  
<212> PRT  
<213> Mus musculus

<400> 100

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Arg Ser Ser Val Val Ser Tyr  
20 25 30

Met Leu Tyr Gln Tyr Lys Pro Gly Thr Ser Ser Lys Leu Trp Ile Tyr  
35 40 45

Arg Ser Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu  
65 70 75 80

Asp Ala Ala Thr Tyr Phe Cys Gln Gln Arg Tyr Pro Gln Tyr  
85 90

<210> 101  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 101

Gln Ile Leu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Gln Tyr Lys Pro Gly Thr Ser Ser Lys Leu Pro Ile Tyr Arg  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Asp Ser Asn Leu Ala Ser Gly Val Phe Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Ser Thr Ile Ser Arg Ser Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln His Arg Ser Ser Phe Tyr  
85 90

<210> 102

<211> 94

<212> PRT

<213> Mus musculus

<400> 102

Glu Ile Leu Leu Thr Gln Ser Pro Ala Ile Ile Ala Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

Asn Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ile Trp Ile Tyr  
35 40 45

Gly Ile Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Phe Ser Phe Thr Ile Asn Ser Met Glu Ala Glu  
65 70 75 80

Asp Val Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro  
85 90

<210> 103

<211> 93

<212> PRT

<213> Mus musculus

<400> 103

Leu Thr Gln Ser Pro Ala Ile Met Ala Ala Ser Leu Gly Glu Lys Val  
1 5 10 15

Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His  
20 25 30

Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Pro Trp Ile Tyr Gly  
Page 39

## CT 008 PCT SEQUENCE LISTING.txt

35 40 45

Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro  
85 90

<210> 104

<211> 96

<212> PRT

<213> Mus musculus

<400> 104

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ala Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser  
20 25 30

Asn Leu His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Thr Lys Phe Trp  
35 40 45

Ile Tyr Arg Thr Ser Asn Leu Ala Ser Glu Val Pro Ala Pro Phe Ser  
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu  
65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Gly Tyr Pro  
85 90 95

<210> 105

<211> 94

<212> PRT

<213> Mus musculus

<400> 105

Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Thr Ala Ala Ser Leu Gly  
1 5 10 15

Gln Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

## CT 008 PCT SEQUENCE LISTING.txt

His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Pro Trp Ile Tyr  
35 40 45

Glu Ile Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu  
65 70 75 80

Asp Ala Ala Ile Tyr Tyr Cys Gln Gln Trp Asn Tyr Pro Leu  
85 90

<210> 106

<211> 96

<212> PRT

<213> Mus musculus

<400> 106

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ala Ala Ser Leu Gly  
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser  
20 25 30

Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Trp  
35 40 45

Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser  
50 55 60

Gly Ser Gly Ala Gly Ile Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu  
65 70 75 80

Ala Glu Asn Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Gly Tyr Pro  
85 90 95

<210> 107

<211> 96

<212> PRT

<213> Mus musculus

<400> 107

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ala Ala Ser Leu Gly  
1 5 10 15

Gln Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser  
20 25 30

## CT 008 PCT SEQUENCE LISTING.txt

Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Pro Leu  
35 40 45

Ile His Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser  
50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu  
65 70 75 80

Ala Glu Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Gly Tyr Pro  
85 90 95

<210> 108

<211> 94

<212> PRT

<213> Mus musculus

<400> 108

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly  
1 5 10 15

Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn Tyr Met  
20 25 30

Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr  
35 40 45

Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu  
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Ser Ser Pro  
85 90

<210> 109

<211> 94

<212> PRT

<213> Mus musculus

<400> 109

Gly Ile Val Leu Thr Gln Ser Pro Thr Thr Met Thr Ala Phe Pro Gly  
1 5 10 15

Glu Asn Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Asn Tyr Ile  
20 25 30

## CT 008 PCT SEQUENCE LISTING.txt

His Trp Tyr Gln Gln Lys Ser Gly Asn Thr Pro Lys Gln Lys Ile Tyr  
35 40 45

Lys Thr Ser Asp Leu Pro Ser Gly Val Pro Thr Leu Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu  
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Gly Tyr Pro  
85 90

<210> 110

<211> 98

<212> PRT

<213> Mus musculus

<400> 110

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Asn Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Val Arg

<210> 111

<211> 98

<212> PRT

<213> Mus musculus

<400> 111

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
Page 43

## CT 008 PCT SEQUENCE LISTING.txt

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Ala Arg

<210> 112

<211> 98

<212> PRT

<213> Mus musculus

<400> 112

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Ala Arg

## CT 008 PCT SEQUENCE LISTING.txt

<210> 113  
<211> 96  
<212> PRT  
<213> Mus musculus

<400> 113

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

<210> 114  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 114

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys  
85 90 95

## CT 008 PCT SEQUENCE LISTING.txt

Ala Arg

<210> 115  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 115

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr  
20 25 30

Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Ala Arg

<210> 116  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 116

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr  
20 25 30

Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe  
Page 46

## CT 008 PCT SEQUENCE LISTING.txt

50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Ala Arg

<210> 117  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 117

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Ala Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Lys Tyr Thr Asn Thr Gly Glu Pro Thr Tyr Gly Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys  
85 90 95

Ala Arg

<210> 118  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 118

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Cys Ala Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Gln Asp Thr Ala Thr  
85 90

<210> 119  
<211> 94  
<212> PRT  
<213> Mus musculus

<400> 119

Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val  
1 5 10 15

Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Ala Gly Met  
20 25 30

Gln Trp Val Gln Lys Met Pro Gly Lys Gly Leu Lys Trp Ile Gly Trp  
35 40 45

Ile Asn Thr His Ser Gly Val Pro Lys Tyr Ala Glu Asp Phe Lys Gly  
50 55 60

Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln  
65 70 75 80

Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys  
85 90

<210> 120  
<211> 93  
<212> PRT  
<213> Mus musculus

<400> 120

Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Arg  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Ala Gly Met Gln  
20 25 30

Trp Val Gln Lys Met Pro Gly Lys Gly Leu Lys Trp Ile Gly Trp Ile  
35 40 45

Asn Thr His Ser Gly Val Pro Lys Tyr Ala Glu Asp Phe Lys Gly Arg  
50 55 60

Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile  
65 70 75 80

Ser Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90

<210> 121

<211> 98

<212> PRT

<213> Mus musculus

<220>

<221> misc\_feature

<222> (39)..(39)

<223> Xaa can be any naturally occurring amino acid

<400> 121

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Thr  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Leu Thr Tyr  
20 25 30

Trp Met Asn Trp Val Lys Xaa Met Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Gln Ile Phe Pro Ala Ser Gly Ser Thr Asn Tyr Asn Glu Met Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg

## CT 008 PCT SEQUENCE LISTING.txt

<210> 122  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 122

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Tyr Ile Tyr Pro Arg Asp Gly Ser Thr Asn Tyr Asn Glu Lys Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg

<210> 123  
<211> 98  
<212> PRT  
<213> Mus musculus

<220>  
<221> misc\_feature  
<222> (39)..(39)  
<223> Xaa can be any naturally occurring amino acid

<400> 123

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Thr  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Leu Thr Tyr  
20 25 30

Trp Met Asn Trp Val Lys Xaa Arg Pro Ala Gln Gly Leu Glu Trp Ile  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Gly Gln Ile Phe Pro Ala Ser Gly Ser Thr Asn Tyr Asn Glu Met Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg

<210> 124  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 124

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Asn Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Trp Ile Tyr Pro Gly Asp Gly Asn Thr Lys Tyr Asn Glu Lys Phe  
50 55 60

Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg

<210> 125  
<211> 98  
<212> PRT  
<213> Mus musculus

<220>  
<221> misc\_feature  
<222> (39)..(39)  
<223> Xaa can be any naturally occurring amino acid

## CT 008 PCT SEQUENCE LISTING.txt

<220>  
<221> misc\_feature  
<222> (45)..(45)  
<223> Xaa can be any naturally occurring amino acid

<400> 125

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Thr  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Thr Tyr  
20 25 30

Trp Met Asn Trp Val Lys Xaa Arg Pro Gly Gln Gly Xaa Glu Trp Ile  
35 40 45

Gly Gln Ile Phe Pro Ala Ser Gly Ser Thr Asn Tyr Asn Glu Met Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val His Phe Cys  
85 90 95

Ala Arg

<210> 126  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 126

Gln Val Gln Leu Leu Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Ser Tyr  
20 25 30

Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile  
35 40 45

Gly Lys Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe  
50 55 60

Lys Gly Lys Ala Lys Phe Thr Ala Asp Ile Ser Ser Asn Thr Ala Tyr  
65 70 75 80

## CT 008 PCT SEQUENCE LISTING.txt

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 127  
<211> 98  
<212> PRT  
<213> Mus musculus

<220>  
<221> misc\_feature  
<222> (39)..(39)  
<223> Xaa can be any naturally occurring amino acid

<400> 127

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Thr  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Leu Thr Tyr  
20 25 30

Trp Met Asn Trp Val Lys Xaa Met Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Ala Ile Phe Pro Ala Gly Gly Ser Thr Asn Tyr Asn Gln Met Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
85 90 95

Ala Arg

<210> 128  
<211> 98  
<212> PRT  
<213> Mus musculus

<400> 128

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Leu  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ile Thr Tyr  
20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Gln Ile Phe Pro Ala Ser Gly Ser Thr Asn Tyr Asn Glu Met Phe  
50 55 60

Glu Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 129  
<211> 105  
<212> PRT  
<213> Mus musculus

<400> 129

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Ala Arg Ser Ser Val Ser Tyr Met  
20 25 30

Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr Arg  
35 40 45

Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly  
50 55 60

Ser Gly Thr Ser Tyr Cys Leu Thr Ile Ser Arg Met Glu Ala Glu Asp  
65 70 75 80

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Phe Pro Leu Thr Phe  
85 90 95

Gly Ser Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 130  
<211> 107

## CT 008 PCT SEQUENCE LISTING.txt

<212> PRT  
<213> Homo sapiens

<400> 130

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Thr Asn Ser Ser Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 131  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 131

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Tyr Ser Thr Phe Pro Leu  
Page 55

## CT 008 PCT SEQUENCE LISTING.txt

85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 132  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 132

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Arg  
85 90 95

Leu Thr Phe Gln Ser Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 133  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 133

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Tyr Asp Ala Ser Asn Lys Ala Thr Gly Val Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ser Arg Lys Trp Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 134  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 134

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 135  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 135

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 136  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 136

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Tyr  
85 90 95

Leu Thr Phe Gln Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 137

## CT 008 PCT SEQUENCE LISTING.txt

<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 137

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 138  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 138

Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

## CT 008 PCT SEQUENCE LISTING.txt

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Tyr Ser Thr Phe Pro Phe  
85 90 95

Leu Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 139  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 139

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

Tyr Asp Thr Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Trp Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 140  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 140

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Trp Phe Pro Leu  
85 90 95

Thr Phe Pro Ser Gly Thr Val Asp Glu Ile Lys  
100 105

<210> 141  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 141

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Tyr Ser Thr Phe Pro Leu  
85 90 95

Thr Phe Gly Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 142  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 142

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Tyr Ser Thr Phe Pro Arg  
85 90 95

Leu Thr Phe Gln Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 143  
<211> 109  
<212> PRT  
<213> Homo sapiens

<400> 143

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr  
20 25 30

Leu Asn Phe Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Tyr Ser Pro Phe Pro Val  
85 90 95

Tyr Leu Thr Phe Gln Ser Gly Thr Lys Leu Glu Ile Lys  
100 105

## CT 008 PCT SEQUENCE LISTING.txt

<210> 144  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 144

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly  
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Tyr  
20 25 30

Leu Ala Phe Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Val  
35 40 45

Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro  
65 70 75 80

Glu Asp Phe Ala Asp Tyr Tyr Cys Gln Gln Arg Glu Trp Phe Pro Leu  
85 90 95

Thr Phe Gln Ser Gly Thr Val Leu Glu Ile Lys  
100 105

<210> 145  
<211> 117  
<212> PRT  
<213> Mus musculus

<400> 145

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu  
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr  
20 25 30

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asp Ser Gly Glu Ser Thr Tyr Ala Glu Glu Phe  
50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr  
65 70 75 80

## CT 008 PCT SEQUENCE LISTING.txt

Leu Gln Ile Asn Asn Leu Asn Asn Glu Asp Thr Ala Thr Tyr Phe Cys  
85 90 95

Val Arg Val Gly Tyr Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser  
100 105 110

Val Thr Val Ser Ser  
115

<210> 146  
<211> 120  
<212> PRT  
<213> Homo sapiens

<400> 146

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Ser His  
20 25 30

Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Gln Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Ser Pro Thr Tyr Ala Gln Gly Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Thr Ser Leu Thr Ala Glu Asp Thr Gly Met Tyr Phe Cys  
85 90 95

Ala Lys Glu Ser His Ser Ser Ala Leu Asp Leu Asp Tyr Trp Gly Gln  
100 105 110

Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 147  
<211> 126  
<212> PRT  
<213> Homo sapiens

<400> 147

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Asn Thr Phe Ser Thr Tyr  
20 25 30

Ala Leu Asn Trp Met Arg Arg Ala Pro Gly Gln Gly Leu Lys Trp Met  
35 40 45

Gly Trp Ile Asn Leu Asn Thr Gly Asn Pro Thr Tyr Ala Gln Asp Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Asn Thr Ala Phe  
65 70 75 80

Leu Gln Ile Ser Ser Leu Gln Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Lys Pro Lys Arg Gly Thr Tyr Arg Arg Gly Tyr Tyr Tyr Pro  
100 105 110

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
115 120 125

<210> 148  
<211> 125  
<212> PRT  
<213> Homo sapiens

<400> 148

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

## CT 008 PCT SEQUENCE LISTING.txt

Ala Arg Gly Gly Tyr Val Trp Gly Ser Tyr Arg Tyr Thr Ala Ala Phe  
100 105 110

Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser  
115 120 125

<210> 149  
<211> 123  
<212> PRT  
<213> Homo sapiens

<400> 149

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Glu Ala Ser Gly Val Thr Phe Thr Gly His  
20 25 30

Tyr Met His Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Glu Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Ala Ser Tyr Cys Gly Tyr Asp Cys Tyr Tyr Phe Phe Asp Tyr  
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 150  
<211> 119  
<212> PRT  
<213> Homo sapiens

<400> 150

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

## CT 008 PCT SEQUENCE LISTING.txt

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Gly Gly Tyr Tyr Gly Ser Gly Ser Asn Tyr Trp Gly Gln Gly  
100 105 110

Thr Leu Val Thr Val Ser Ser  
115

<210> 151  
<211> 123  
<212> PRT  
<213> Homo sapiens

<400> 151

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Gly His  
20 25 30

Tyr Met His Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Ala Ser Tyr Cys Gly Tyr Asp Cys Tyr Tyr Phe Phe Asp Tyr  
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

## CT 008 PCT SEQUENCE LISTING.txt

115 120

<210> 152  
<211> 122  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 152

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Val Lys Trp Glu Gln Pro Ile Asp Ala Pro Phe Asp Tyr Trp  
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 153  
<211> 123  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 153

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Gly His  
20 25 30

Tyr Met His Trp Val Gly Gln Ala Thr Gly Gln Gly Leu Glu Trp Met  
35 40 45

## CT 008 PCT SEQUENCE LISTING.txt

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Ala Ser Tyr Cys Gly Tyr Asp Cys Tyr Tyr Phe Phe Asp Tyr  
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 154

<211> 126

<212> PRT

<213> Homo sapiens

<400> 154

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Asp Gly Tyr Tyr Asp Ser Asn Gly Tyr Tyr Ser Gly Tyr  
100 105 110

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120 125

<210> 155

<211> 121

## CT 008 PCT SEQUENCE LISTING.txt

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Val Gln Trp Leu Gly Leu Thr Gly Pro Asn Asp Tyr Trp Gly  
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

&lt;210&gt; 156

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 156

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Ala Met Asn Trp Val Gly Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
Page 70

## CT 008 PCT SEQUENCE LISTING.txt

65 70 75 80

Leu Gln Ile Cys Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

<210> 157  
<211> 125  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 157

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe  
50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr  
65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95Ala Arg Asp Gly Ile Val Val Val Pro Ala Ala Ile Pro His Tyr Phe  
100 105 110Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120 125<210> 158  
<211> 118  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 158

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe  
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr  
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Asn Asn Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr  
100 105 110

Leu Val Thr Val Ser Ser  
115

<210> 159  
<211> 98  
<212> PRT  
<213> Homo sapiens

<400> 159

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Asp Pro Thr Tyr Ala Gln Gly Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr  
65 70 75 80

Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg

## CT 008 PCT SEQUENCE LISTING.txt

<210> 160  
<211> 119  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (108)..(108)  
<223> Xaa can be any naturally occurring amino acid

<400> 160

Gln Val Gln Leu Val His Ser Gly Ser Glu Phe Lys Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser  
20 25 30

Val Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe  
50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Thr Thr Thr Tyr  
65 70 75 80

Leu Gln Ile Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Glu Leu Arg Asn Asp His Tyr Val Trp Xaa Asn Tyr Arg Pro  
100 105 110

Pro Leu Ser Tyr Trp Gly Gln  
115

<210> 161  
<211> 106  
<212> PRT  
<213> Mus musculus

<220>  
<221> misc\_feature  
<222> (94)..(94)  
<223> Xaa can be any naturally occurring amino acid

<400> 161

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met  
20 25 30

His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr  
35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser  
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu  
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Xaa Leu Thr  
85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys  
100 105

<210> 162

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (31)..(32)

<223> Xaa can be any naturally occurring amino acid

<400> 162

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Leu Val Xaa Xaa  
20 25 30

Ser Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala  
35 40 45

Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro  
50 55 60

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile  
65 70 75 80

Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr  
85 90 95

## CT 008 PCT SEQUENCE LISTING.txt

Asn Ser Leu Pro Glu Glu Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu  
100 105 110

Ile Lys

<210> 163

<211> 119

<212> PRT

<213> *Mus musculus*

<400> 163

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala  
1 5 10 15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Pro Asn Ile Lys Asp Thr  
20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Arg Ile Asp Pro Asp Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys  
50 55 60

Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala  
65 70 75 80

Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr  
85 90 95

Cys Ala Arg Gly Gly Tyr Leu Arg Arg Asp Asp Tyr Trp Gly Gln Gly  
100 105 110

Thr Ser Val Thr Val Ser Ser  
115

<210> 164

<211> 128

<212> PRT

<213> *Homo sapiens*

<220>

<221> misc\_feature

<222> (115)..(115)

<223> Xaa can be any naturally occurring amino acid

<400> 164

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

## CT 008 PCT SEQUENCE LISTING.txt

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr  
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

Gly Trp Ile Asn Pro Tyr Gly Asn Gly Asp Thr Asn Tyr Ala Gln Lys  
50 55 60

Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala  
65 70 75 80

Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr  
85 90 95

Cys Ala Arg Ala Pro Gly Tyr Gly Ser Gly Gly Cys Tyr Arg Gly  
100 105 110

Asp Tyr Xaa Phe Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120 125

<210> 165

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 165

Ser Asn Asp Thr Glu

1 5

<210> 166

<211> 11

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<400> 166

Asp Leu Tyr Val Ile Ser Asn Phe His Gly Thr  
1 5 10

<210> 167

<211> 5

<212> PRT

## CT 008 PCT SEQUENCE LISTING.txt

<213> Artificial

<220>

<223> synthetic peptide

<400> 167

Ser Asn Thr Lys Gly

1 5

<210> 168

<211> 7

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 168

Phe Tyr Asn Ala His Ser Arg

1 5

<210> 169

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 169

Met Leu Val Ile Phe

1 5

<210> 170

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 170

Gln Ser Gly Phe Leu

1 5

<210> 171

<211> 10

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 171

## CT 008 PCT SEQUENCE LISTING.txt

Asn Phe Gly Ser Arg Asp His Thr Tyr Val  
1 5 10

<210> 172  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic peptide

<400> 172

Asn Tyr Trp Thr Ser Arg Gln His Ala Asp  
1 5 10

<210> 173  
<211> 12  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic peptide

<400> 173

Glu Asn Gly His Thr Ser Arg Ala Gln His Ala Asp  
1 5 10

<210> 174  
<211> 11  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic peptide

<400> 174

Asp Tyr Thr Val Leu His Asn Ile Trp Pro Ser  
1 5 10

<210> 175  
<211> 7  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic peptide

<400> 175

Pro Leu Tyr Arg Ile Trp Phe  
1 5

## CT 008 PCT SEQUENCE LISTING.txt

<210> 176

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 176

Thr Ala Val Gly Ser

1 5

<210> 177

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 177

Met Ile Val Leu Thr

1 5

<210> 178

<211> 6

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 178

Arg Thr Lys His Gly Leu

1 5

<210> 179

<211> 9

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 179

Ile His Tyr Phe Thr Asn Cys Glu Asp

1 5

<210> 180

<211> 7

<212> PRT

<213> Artificial

## CT 008 PCT SEQUENCE LISTING.txt

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 180

Tyr Ala Trp Gly Thr Leu Val  
1 5

&lt;210&gt; 181

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 181

His Glu Asn Gln Ser Tyr Thr  
1 5

&lt;210&gt; 182

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 182

Leu Ile Val Thr Ser Asn  
1 5

&lt;210&gt; 183

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 183

Ile Leu Phe Met Val  
1 5

&lt;210&gt; 184

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 184

## CT 008 PCT SEQUENCE LISTING.txt

Ala Leu Val Tyr Phe  
1 5

<210> 185  
<211> 6  
<212> PRT  
<213> Artificial  
  
<220>  
<223> synthetic peptide  
  
<400> 185

Arg Lys Gly Ser His Asn  
1 5

<210> 186  
<211> 7  
<212> PRT  
<213> Artificial  
  
<220>  
<223> synthetic peptide  
  
<400> 186

Tyr His Val Ile Ser Asp Gly  
1 5

<210> 187  
<211> 6  
<212> PRT  
<213> Artificial  
  
<220>  
<223> synthetic peptide  
  
<400> 187

Tyr Trp Gly Ala Thr Leu  
1 5

<210> 188  
<211> 11  
<212> PRT  
<213> Artificial  
  
<220>  
<223> synthetic peptide  
  
<400> 188

Arg Glu Trp Tyr Gly Gln Val Leu Asn Lys Ala  
1 5 10

<210> 189

## CT 008 PCT SEQUENCE LISTING.txt

<211> 5

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 189

Asp Leu Asn Ser Tyr

1 5

<210> 190

<211> 7

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 190

Ala Gly Tyr Ser Lys Thr Asn

1 5

<210> 191

<211> 6

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 191

Asn Ser Thr Lys Asp Gly

1 5

<210> 192

<211> 8

<212> PRT

<213> Artificial

<220>

<223> synthetic peptide

<400> 192

Tyr Arg Glu Asp Gly Val Ser Ala

1 5

<210> 193

<211> 9

<212> PRT

<213> Artificial

<220>

CT 008 PCT SEQUENCE LISTING.txt

<223> synthetic peptide

<400> 193

Lys Asn Thr Ser Asp Arg Gly Phe Tyr  
1 5